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I. Introduction 
 Chagas disease is a serious parasitic infection that affects at 
least 6 million people in the world.1 An estimated 300,000 Chagas 
disease patients live in the United States.2 Until recently, no FDA 
approved treatment for Chagas disease existed.3 The FDA’s Priority 
Review Voucher incentive program was a key factor in the recent 
FDA approval of benznidazole for the treatment of Chagas Disease.4 
                                                 
1 Chagas Disease (American Trypanosomisasis), WORLD HEALTH 
ORG. (last updated Mar. 2017), 
http://www.who.int/mediacentre/factsheets/fs340/en/ [hereinafter 
WHO] (fact sheet) (stating that Chagas disease is “also known as 
American Trypanosomiasis).  




3 Thomas Morrow, MD, FDA Gives First-Ever Approval of Drug to 
Treat Chagas Disease, (Nov. 2017), 
https://www.managedcaremag.com/archives/2017/11/fda-gives-first-
ever-approval-drug-treat-chagas-disease (“Until recently, there was 
no treatment bearing the FDA’s stamp of approval for Chagas’ [sic] 
disease.”). 
4 See Press Release, FDA, FDA Approves First Treatment for 
Chagas Disease (Aug. 29, 2017), 
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/
ucm573942.htm [hereinafter Press Release FDA Approves] 
(explaining that the FDA granted a priority review voucher to the 
drug sponsor of benznidazole and that “[t]he FDA is committed to 
making available safe and effective therapeutic options to treat 
tropical diseases”). 
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 This article describes the role of the FDA Priority Review 
Voucher program in the recent FDA approval of benznidazole for 
Chagas disease. This article’s first section details the background 
and current status of the FDA Priority Review Voucher program.5 
The next section explains the sale of priority review vouchers.6 This 
article then explores the impact, benefits, and limitations of the 
Priority Review Voucher Program.7 Part II ends with a brief 
description of the FDA’s Orphan Drug status designation.8 
 Part III begins by describing Chagas disease and its 
discovery.9 This part then addresses the history of Chagas disease 
treatments.10 This article then explains the events surrounding the 
recent FDA approval of benznidazole for the treatment of Chagas 
disease.11 This article concludes by assessing the FDA Priority 
Review Voucher program’s role in the benznidazole approval and 
addresses legislative concerns going forward.12 
II. History and Background Section 
A.  Relationship Between Patent Law and Pharmaceutical Companies 
Many diseases in developing countries are untreated because 
patent law monopolies price the necessary medications out of the 
financial reach of poor countries’ inhabitants.13 Although many 
                                                 
5 See infra Parts IIA., B., C. 
6 See infra Part IID. 
7 See infra Parts IIE., F. 
8 See infra Part IIG. 
9 See infra Parts IIIA., B. 
10 See infra Part IIIC.  
11 See infra Part IV. 
12 See infra Part V. 
13 Robert C. Bird, Developing Nations and the Compulsory License: 
Maximizing Access to Essential Medicine While Minimizing 
3Published by Mitchell Hamline Open Access, 2018
                    CYBARIS®, AN INTELLECTUAL PROPERTY LAW REVIEW                              235 
 
factors contribute to the lack of available medications in developing 
countries, the tight relationship between U.S. governmental patent 
law and multinational pharmaceutical corporations provides the 
cornerstone to “this global health crisis.”14 Multinational 
pharmaceutical corporations utilize government-approved 
monopolies to control medications’ use and sale.15 Patents to 
medications allow pharmaceutical corporations to raise prices into 
the unaffordable range for patients who need the medications the 
most.16 Multinational corporations claim that high research and 
development costs impede their ability to lower medication prices.17 
Additionally, multinationals cite the potential for trafficking of 
                                                 
Investment Side Effects, 37 J.L. MED. & ETHICS 209, 209 (2009) 
(“Many of the health problems facing the developing world do not 
arise from a lack of understanding of complex diseases. Rather, the 
problem arises from a striking lack of availability of life saving 
medications for the consumers that need these medicines the most.”). 
14 Id. (stating that “the publicity spotlight . . . has shined largely on 
the alliance of strong, government-legislated patent law and the 
multinational corporation” as a cause of poor medication access in 
developing countries). 
15 Id.; Marcia Angell, The Truth About Drug Companies, THE N.Y. 
REV. OF BOOKS (July 15, 2004), 
https://alojamientos.uva.es/guia_docente/uploads/2013/478/46299/1/
Documento2.pdf (stating that the pharmaceutical industry is “utterly 
dependent on government-granted monopolies—in the form of 
patents and Food and Drug Administration (FDA)-approved 
exclusive marketing rights”).  
16 Bird, supra note 13 at 209 (stating that “[m]ultinationals owning 
patents to medicines raise prices” such that the needed treatments 
“become unaffordable to the poorest consumers who need them”). 
17 Bird, supra note 13 at 209; Angell, supra note 15 at 1 (quoting a 
pharmaceutical company spokeswoman as explaining that “’[p]rice 
increases are not uncommon in the industry and that allows us to 
invest in R&D’” (research and development)).  
4https://open.mitchellhamline.edu/cybaris/vol9/iss2/3
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medications from developing countries to wealthier nations.18 
However, critics believe that multinationals sacrifice impoverished 
countries’ citizens’ health to increase profit margins.19 
                                                 
18 Bird, supra note 13 at 209. 
19 Bird, supra note 13 at 209; Angell, supra note 15 at 3 (stating that 
research and development costs comprise a minor portion of 
(pharmaceutical corporations’ spending and that “the prices drug 
companies charge have little relationship to cost of making drugs 
and could be cut dramatically without coming anywhere close to 
threatening [research and development]”). 
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B. United States Food and Drug Administration Priority 
Review  
 In 2006, a trio of Duke University faculty members published 
a paper suggesting the use of priority review vouchers to incentivize 
drug companies to manufacture “essential drugs in developing 
countries.”20 The paper proposed that the FDA grant transferrable 
vouchers that would significantly decrease FDA approval times for 
drugs treating neglected tropical diseases (“NTDs”).21 The voucher 
idea “caught the attention” of members of Congress, and in 2007, 
President Bush signed the Food and Drug Administration Amendment 
Act (FDAAA) that included provisions for priority review vouchers 
(“PRVs”).22 The Act states that the FDA may issue a PRV to a 
pharmaceutical company that receives approval for a new drug 
application (“NDA”) or a biologics license application (“BLA”) for a 
new chemical entity (“NCE”) to treat an NTD.23 The pharmaceutical 
company may then apply the PRV toward a different medicine that 
the company wishes to market.24 Conversely, a pharmaceutical 
company may sell its PRV to another drug manufacturer.25 As of 
2016, the average sale price for a PRV was $200 million.26 Thus, the 
PRV acts as a “prize” to encourage pharmaceutical companies to 
complete the required steps for FDA approval.27 In 2012, President 
Barack Obama signed the Food and Drug Administration Safety and 
Innovation Act (FDASIA),  which provided the FDA with authority 
to grant PRV for treatments of rare pediatric diseases.28 
                                                 
20 David B. Ridley et al., Developing Drugs for Developing 
Countries, 25 HEALTH AFFAIRS 313, 313 (2006), 
https://www.healthaffairs.org/doi/pdf/10.1377/hlthaff.25.2.313 
[hereinafter Ridley, Developing Drugs] (listing Chagas disease as an 
example of a “neglected disease”). 
6https://open.mitchellhamline.edu/cybaris/vol9/iss2/3
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21 Id. at 322 (explaining that “[i]n a well-functioning voucher 
market,” priority review vouchers would “speed access to highly 
valued treatments,” allowing drugs for treating diseases in 
developing countries to reach patients more quickly); David Ridley, 
Priority Review Vouchers, PRIORITY REV. VOUCHERS (last visited 
Dec. 16, 2017), http://priorityreviewvoucher.org [hereinafter Ridley, 
Priority Review Vouchers] (listing the NTDs eligible to PRVs 
including blinding trachoma, cholera, dengue, leprosy, malaria, 
tuberculosis, as well as Chagas disease, which the FDA added in 
2015); Why are some tropical diseases called “neglected”?, WORLD 
HEALTH ORG. (Jan. 2012), http://www.who.int/features/qa/58/en/ 
(“Neglected tropical diseases persist in under conditions of poverty 
and are concentrated almost exclusively in impoverished populations 
in the developing world.”). 
22 Jonathan Berman, The Tropical Disease Priority Review Voucher: 
A Game-Changer for Tropical Disease Products, 96 AM. J. 
TROPICAL MED. HYGIENE 11, 12 (2017), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239674/; 
Alexander Gaffney, Regulatory Explainer: Everything You Need to 
Know About FDA’s Priority Review Vouchers, REG. AFF.  PROFS. 
SOC’Y (Nov. 29, 2017), http://www.raps.org/Regulatory-
Focus/News/2015/07/02/21722/Regulatory-Explainer-Everything-
You-Need-to-Know-About-FDA’s-Priority-Review-Vouchers/; 
Ridley, Priority Review Vouchers, supra note 21; see Food and Drug 
Administration Amendment Act of 2007, Pub. L. No. 110-85, 121 
Stat. 823, https://www.gpo.gov/fdsys/pkg/STATUTE-
121/pdf/STATUTE-121-Pg823.pdf.  
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23 21 C.F.R. § 314.108 (2016) (“New chemical entity means a drug 
that contains no active moiety that has been approved by the FDA in 
any other NDA submitted under section 505(b) of the Federal Food, 
Drug, and Cosmetic Act.”); Berman, supra note 22 at 12; Biologics 
License Applications (BLA) Process (CBER), U.S. FOOD & DRUG 
ADMIN. (last updated Nov. 5, 2015), 
https://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprova
lProcess/BiologicsLicenseApplicationsBLAProcess/default.htm 
(“The Biologics License Application (BLA) is a request for 
permission to introduce . . . a biologic product into interstate 
commerce (21 CFR 602.1).”); New Drug Application (NDA), U.S. 
FOOD & DRUG ADMIN. (last updated March 29, 2016), 
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrug
sareDevelopedandApproved/ApprovalApplications/NewDrugApplic
ationNDA/default.htm (“The NDA application is a vehicle through 
which drug sponsors formally propose that the FDA approve a new 
pharmaceutical for sale and marketing in the U.S.”). 
24 Berman, supra note 22 at 12. 
25 Id. (“The PRV is transferrable and can be sold for use with any 
other product.”).  
26 David B. Ridley, Priorities for the Priority Review Voucher, 96 
AM. J. TROPICAL MED. HYGIENE 14, 15 (2017), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239680/ 
[hereinafter Ridley, Priorities] (explaining that as of June 2016, 4 
out of the 10 PRV recipients had sold their vouchers); see also 
Gaffney, supra note 22 (stating that as of June 2017, PRV sale prices 
have ranged from $ 67 million to $350 million). 
27 Ridley, Developing Drugs, supra note 20 at 316–18 (explaining 
“push” and “pull” mechanisms for stimulating drug development and 
describing the PRV strategy a “pull mechanism”); Ridley, Priority 
Review Vouchers, supra note 24 (referring to a PRV as a “prize” in 
the context of discussing the limitations of the PRV program). 
8https://open.mitchellhamline.edu/cybaris/vol9/iss2/3
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sec360ff.pdf (defining a “rare pediatric disease” as one that 
“primarily affects individuals aged birth to 18 years” and “which (A) 
affects less than 200,000 persons in the United States, or (B) affects 
more than 200,000 persons in the United States and for which there 
is no reasonable expectation that the cost of developing and making 
available in the United States a drug for such disease or condition 
will be recovered from sales in the United States of such drug”); 
FDA: Recently Signed PDUFA 5 Provisions to Address Drug 
Shortages, POL’Y & MED. (July 18, 2012), 
http://www.policymed.com/2012/07/fda-recently-signed-pdufa-5-
provisions-to-address-drug-shortages.html; Rare Pediatric Disease 
Priority Review Voucher Program, U.S. FOOD & DRUG ADMIN. (last 
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C. FDA’s Priority Review Vouchers 
  All prescription medications marketed in the United States 
must receive FDA approval.29 To receive approval, each drug must 
undergo the FDA’s review process.30 The review process is a “two-
tiered” system that includes standard review and priority review.31 
Drugs with a standard review designation normally receive an FDA 
decision concerning approval 10 months after a manufacturer submits 
an NDA.32 In contrast, the decision time for drugs with a priority 
review designation is 6 months.33 The FDA grants a standard review 
or a priority review designation for all NDAs and BLAs.34 
Additionally, a drug manufacturer may request a priority review 
designation.35 PRVs provide yet another mechanism by which a drug 
may receive priority review designation.36 
                                                 
29 What is the Approval Process for a New Prescription Drug?, U.S. 
FOOD & DRUG ADMIN. (last updated Nov. 11, 2017) 
https://www.fda.gov/AboutFDA/Transparency/Basics/ucm194949.ht
m.  
30 Priority Review Vouchers, U.S. FOOD & DRUG ADMIN. (last 
updated Sept. 9, 2014), 
https://www.fda.gov/ForPatients/Approvals/Fast/ucm405405.htm 
[hereinafter FDA Priority Review].  
31 Id.  
32 Id.; Step 4: FDA Review, U.S. FOOD & DRUG ADMIN. (last updated 
Apr. 26, 2017), 
https://www.fda.gov/ForPatients/Approvals/Drugs/ucm405570.htm.  
33 FDA Priority Review, supra note 30.  
34 Id. 
35 Id.  
10https://open.mitchellhamline.edu/cybaris/vol9/iss2/3
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36 Gaffney, supra note 22 (detailing the differences between “What 
the Priority Review Designation Process Normally Looks Like” and 
“How the Priority Review Voucher System Works” in a chart). 
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 The FDA provides priority review designations to drugs that 
“would be significant improvements in the safety or effectiveness of 
the treatment, diagnosis, or prevention of serious conditions when 
compared to standard applications.”37 A priority review designation 
does not decrease the clinical trial period’s length, nor does it “alter 
the scientific standard for approval or the quality of evidence 
necessary.”38 Instead, the priority review designation “is intended to 
direct overall attention and resources to the evaluation of such 
applications.”39 The FDA also grants priority review designation to 
treatments for pediatric patients and for infectious diseases.40Priority 
review is one of four FDA approaches that strive to increase the speed 
with which drugs become available in the United States.41 
                                                 
37 FDA Priority Review, supra note 30 (listing “elimination or 
substantial reduction of a treatment-limiting drug reaction; 
documented enhancement of patient compliance,” and “evidence of 
safety and effectiveness in a new subpopulation” as examples of 
“significant improvement”);  
38 Id.  
39 U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: EXPEDITED 
PROGRAMS FOR SERIOUS CONDITIONS—DRUGS AND BIOLOGICS 24 
(2014), 
https://www.fda.gov/downloads/drugs/guidancecomplianceregulator
yinformation/guidances/ucm358301.pdf [hereinafter GUIDANCE].  
40 Id. (describing a “supplement that proposes a labelling change 
pursuant to report on a pediatric study” and an “application for a 
drug that has been designated  as a qualified infectious disease 
product”). 
12https://open.mitchellhamline.edu/cybaris/vol9/iss2/3
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41 Fast Track, Breakthrough Therapy, Accelerated Approval, 
Priority Review, U.S. FOOD & DRUG ADMIN. (last updated Sept. 4, 
2015), https://www.fda.gov/ForPatients/Approvals/Fast/default  
(noting that although “each of [the four] approaches implies speed,” 
they constitute “four distinct and successful approaches to making 
such drugs as rapidly as possible”). 
13Published by Mitchell Hamline Open Access, 2018
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D. Sale of PRVs 
 Another beneficial characteristic of PRVs is their 
transferability.42 Instead of utilizing the PRV to obtain priority review 
for one of its own products, a PRV holder may sell the PRV to another 
drug manufacturer.43 To illustrate the potential economic value of a 
PRV, consider a small pharmaceutical company with a PRV for an 
NTD.44 The PRV’s value may be essentially equivalent to the 
company’s value.45 Not surprisingly, new business models have come 
into existence with the goal of utilizing the PRV program as a valuable 
financial tool.46 
                                                 
42 Ridley, Priority Review Vouchers, supra note 21. 
43 Gaffeny, supra note 22 (explaining that a PRV holder can either 
redeem the voucher for its own use or sell the voucher to “another 
company, which might to have its own drug reviewed in a six-month 
timeline”). 
44 See David B. Ridley, Fuqua Research into Action: The Priority 
Review Voucher, https://faculty.fuqua.duke.edu/~dbr1/voucher/ 
[hereinafter Ridley, Fuqua Research] (video) (giving an example of 
a company who held a voucher from the manufacturing of a drug for 
leishmaniasis). 
45 Id. (describing bankers seeking information concerning the value 
of a PRV to determine the value of a company). 
14https://open.mitchellhamline.edu/cybaris/vol9/iss2/3
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E. Impact and Benefits of PRVs 
 A PRV provides a drug manufacturer with a priority review 
designation for use with a future drug.47 The manufacturer does not 
use the PRV for the NTD medication; instead, the manufacturer uses 
the PRV for a different drug.48 Although the PRV-qualifying NTD 
drug does not utilize a PRV, the NTD drug must also qualify for 
priority review “on its own merit.”49A PRV allows a new drug to 
arrive on the U.S. market sooner than its competitors, thus increasing 
the potential for a pharmaceutical company to release a blockbuster 
drug.50  
                                                 
46 Chris Bialas, Analyzing the FDA Priority Review Voucher 
Programs Stimulation of Research and Public Health Impact, 3 






Impact.pdf (“This interest has even spawned new business models 
based on the development of target designation treatments in order to 
acquire and sell PRVs.”) 
47 Gaffeny, supra note 22; Ridley, Priority Review Vouchers, supra 
note 21.  
48 Ridley, Priorities, supra note 26 (“Thus, two drugs are involved: 
the drug that wins a bonus priority review and the drug that uses the 
bonus priority review.”). 
49 Ridley, Priorities, supra note 26 at 15.  
50 Id.; David B. Ridley, Fuqua Research, supra note 44. 
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 Three value sources for PRV holders exist.51 First, a PRV 
allows a manufacturer to release its product into the market sooner 
than standard review would allow.52 Second, a PRV provides a longer 
on-market experience for the pharmaceutical company’s product.53 
Third, a PRV provides a drug manufacturer with “competitive 
benefits” that may allow the voucher holder to “launch” their product 
closer to or even before a competitor’s product.54  
                                                 
51 Ridley, Fuqua Research, supra note 44.  
52 Id. (noting that reaching the market earlier increases the “time 
value of money”). 
53 Id. (explaining that “you launch earlier and have the same 
effective patent expiration date, in many cases”).  
54 Id.  
16https://open.mitchellhamline.edu/cybaris/vol9/iss2/3
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 The PRV program provides two important benefits to 
healthcare.55 First, PRVs encourage drug companies to complete the 
necessary research and development for rare and neglected disease 
treatments.56 Without the attraction of a PRV, few drug companies 
would invest in medicines to treat NTDs.57 Accordingly, before the 
PRV program, few pharmaceutical companies applied for patents on 
their “essential medicines” distributed to low-to mid-income 
countries.58  
                                                 
55 Ridley, Priority Review Vouchers, supra note 21. 
56 GUIDANCE, supra note 39 (requiring clinical trials, clinical testing, 
“randomized trials, other types of controls . . . for example, historical 
controls” as “an attempt to show superiority relating to either safety 
or effectiveness”); Ridley, Priority Review Vouchers, supra note 21.  
57 Gaffeny, supra note 22 (“FDA’s priority review vouchers . . . are 
incentives meant to spur the development of new treatments for 
diseases that would otherwise not attract development interest from 
companies due to the cost of development and the lack of market 
opportunities.”). 
58 Amir Attaran, How Do Patents and Economic Policies Affect 
Access to Essential Medicines in Developing Countries? 23 HEALTH 
AFFAIRS 155, 155, 159 (2004), 
https://www.healthaffairs.org/doi/pdf/10.1377/hlthaff.23.3.155 
(finding that pharmaceutical companies usually did not seek patents 
in developing countries, even when they legally had the option).  
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 Second, PRV program allows “potential blockbuster” drugs to 
reach U.S. patients more quickly.59 Data suggests that priority review 
status increases a drug’s likelihood of obtaining blockbuster status.60 
While some drugs achieve blockbuster status without priority review 
designation, pharmaceutical companies and patients lose the benefits 
of expedited FDA approval.61 Because the FDA “direct[s] overall 
attention and resources” to drugs with priority review status, the 
voucher holder must pay a fee to redeem the PRV.62 This user fee 
allows the FDA to obtain the necessary resources to expedite the 
review of the PRV drug without delaying the review of other 
medications.63Thus, the PRV program provides sources of 
medications to treat NTD without incurring U.S. taxpayer costs or 
delayed FDA review of other medications.64 The PRV program 
inspired the United States Patent and Trademark Office to create an 
awards competition to recognize “innovators who use game-changing 
technology to meet global humanitarian challenges.”65 
                                                 
59 Ridley, Priority Review Vouchers, supra note 21; What Is a 
Blockbuster Drug?, THE MOTLEY FOOL (last visited Dec. 18, 2017), 
https://www.fool.com/knowledge-center/what-is-a-blockbuster-
drug.aspx (“Blockbuster drugs are those that generate at least $1 
billion is revenue a year for the pharmaceutical companies that 
produce them.”). 
60 Ridley, Developing Drugs, supra note 20 (noting that during the 
1990s, “fourteen of the twenty-nine ‘blockbuster drugs’ . . .  were 
classified as priority”). 
61 Id. (listing Zocor, Norvasc, Cozaar, and Zyprexa and examples of 
drugs that “[h]ad priority review vouchers been available, these 
drugs could have helped patients sooner and earned higher returns”). 
18https://open.mitchellhamline.edu/cybaris/vol9/iss2/3
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62 Notice, Fee for Using a Tropical Disease Priority Review Voucher 
in Fiscal Year 2017, 81 Fed. Reg. 67356 
https://www.federalregister.gov/documents/2016/09/30/2016-
23623/fee-for-using-a-tropical-disease-priority-review-voucher-in-
fiscal-year-2017 (stating that the fee category for an “[a]pplication 
submitted with a tropical disease priority review voucher in addition 
to the normal PDUFA fee” was $2,706,000 for the fiscal year 2017);  
Tropical Disease Priority Review Voucher Program, U.S. FOOD & 
DRUG ADMIN. (last updated May 24, 2017), 
https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalPro
ductsandTobacco/CDER/ucm534162.htm (noting in a table that fees 
for tropical disease PRV have ranged from $2,325,000 to $5,280,000 
from 2011 to 2018 and that the Tropical Disease PRV User Fee for 
the 2018 fiscal year will be $2,830,000; Ridley, Priority Review 
Vouchers, supra note 21 (“By moving one drug to faster review, 
there is the potential to slow other drugs.”). 
63 Ridley, Priority Review Vouchers, supra note 21. 
64 Berman, supra note 22 at 13. 
65 Request for Comments on Incentivizing Humanitarian 
Technologies and Licensing Through the Intellectual Property 
System, 75 Fed. Reg. 57261 (Sept. 20, 2010) 
https://www.federalregister.gov/documents/2010/09/20/2010-
23395/request-for-comments-on-incentivizing-humanitarian-
technologies-and-licensing-through-the;  Patents for Humanity, 
UNITED STATES PAT. & TRADEMARK OFF. (last updated Nov. 17, 
2017), https://www.uspto.gov/patent/initiatives/patents-
humanity/learn-more;  Ridley, Priority Review Vouchers, supra note 
21.  
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F. Limitation, risks, and criticisms of the PRV Program 
 The PRV program contains inherent risk and limitations.66 
Most importantly, the FDA is not required to approve a PRV holder’s 
product.67 The FDAAA and FDASIA state that the FDA will come to 
a decision on a PRV holders NDA—not that the FDA is obligated to 
approve the drug.68 Additionally, although the FDA pledges to 
allocate resources to expedite the review of a priority review drug, the 
FDA does not guarantee completion of review in the six-month time 
frame.69 
                                                 
66 Gaffeny, supra note 22. 
67 Id.  
68 U.S. FOOD & DRUG ADMIN., TROPICAL DISEASE PRIORITY REVIEW 
VOUCHERS: GUIDANCE FOR INDUSTRY 6 (2016), 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulat
oryInformation/Guidances/UCM080599.pdf [hereinafter TDPRV 
GUIDANCE] (“Note that an FDA review within a specific time frame 
does not mean an application will be approved within that time 
frame. The term review and act on is understood to mean the 
issuance of an approval or complete response letter after the review 
of a filed application.”); Id. (noting that an action letter may not 
contain approval); Gaffeny, supra note 22(“As Novartis proved in 
the first-ever use of a priority review voucher, FDA will not 
necessarily approve a product just because its sponsor used a 
voucher. Priority review . . . will not save a bad drug from being 
rejected.”). 
20https://open.mitchellhamline.edu/cybaris/vol9/iss2/3
                    CYBARIS®, AN INTELLECTUAL PROPERTY LAW REVIEW                              252 
 
                                                 
69 GUIDANCE, supra note 39 at 25 (“A priority review designation 
means the FDA’s goal is to take action on the marketing application 
within 6 months of receipt (compared with 10 months under standard 
review).”); TDPRV GUIDANCE, supra note 68 at 5 (stating that the 
FDA has “committed to a goal to review and act on 90 percent pf 
priority new molecular entity (NME) NDA and original BLA 
submissions within 6 month of the 60-day filing date, and 90 percent 
of priority non-NME original NDA  submissions within 6 months of 
receipt”); Gaffeny, supra note 22 (describing the FDA’s lack of 
obligation to meet a fixed deadline for approval as a “little-known 
limitation”). 
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 Critics of the PRV program highlight several weaknesses of 
PRVs.70 First, the drug applying for a PRV must itself earn a priority 
review designation. 71 Second, the costs for completing clinical trials 
are often higher for NTDs than for rare pediatric diseases, thus making 
PRVs less valuable to drug manufacturers developing NTD treatments 
than those developing rare pediatric disease treatments.72 Third, 
Congress could decide not to renew the voucher program, thus 
exposing drug companies to investment risk.73 Additionally, variables 
such as timing, supply, and competition make predicting a PRV’s sale 
value challenging.74 Fourth, drug manufacturers may receive PRV for 
drugs that are currently available outside the United States, thus 
defeating the program’s goal of developing novel treatments.75 
Finally, the PRV program does not ensure that the drugs for treating 
NTDs will be available or affordable.76 
                                                 
70 See Berman, supra note 22 at 13; Ridley, Priorities, supra note 26 
at 15.  
71 TDPRV GUIDANCE, supra note 68 at 2 (stating that a drug 
application sponsor is eligible for a tropical disease PRV if “[t]he 
application might otherwise be eligible for a priority review”); 
Berman, supra note 22 at 11 (stating that the requirement the NDA 
product must itself have priority review has “at least three important 
ramifications”); Ridley, Priorities, supra note 26 at 14. 
72 Berman, supra note 22 at 12 (“Unlike rare pediatric diseases . . . 
tropical diseases . . . require large-scale trials”); Ridley, Priorities, 
supra note 26 at 14. 
73 Berman, supra note 22 at 12 (“There is legislative risk around the 
programs very existence or the rules around its application.”). 
74 Id. (explaining that “the timing of a voucher sale is more art than 
science”). 
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75 Helen Branswell, How a System Meant to Develop Drugs for Rare 
Diseases Broke Down, STAT (Nov. 28, 2015), 
https://www.statnews.com/2015/11/28/priority-review-vouchers-
rare-diseases/ (explaining the first PRV recipient was a drug 
manufacturer of a malaria treatment that “had been licensed outside 
the U.S. since 2001 and was already widely in use”); see also David 
Ridley, How to Put an Ebola Treatment on Drugmakers’ Radar, 
SFGATE (Oct. 12, 2014), 
http://www.sfgate.com/opinion/openforum/article/Congress-should-
offer-vouchers-to-develop-ebola-5818174.php (stating that 
“Congress should restrict eligibility for the voucher to novel 
products that have not been approved in other countries more than 
two years prior to FDA submission”). 
76 Ridley, Priorities, supra note 26 at 14; Branswell, supra note 75 
(“Drug makers that earn priority review vouchers don’t have to 
guarantee that the drugs will actually be available, or sold at an 
affordable price.”). 
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G. The Orphan Drug Development Program 
 In 1984, President Ronald Reagan signed the Orphan Drug 
Act.77 The Act provided incentives for pharmaceutical companies to 
market treatments for rare diseases.78 These incentives include tax 
credits, market exclusivity, and fast-track designation.79 A drug may 
obtain orphan status in two ways.80 First, the FDA may grant a drug 
may orphan status if the drug provides a treatment for a rare 
disease.81 Second, the FDA may grant orphan status to a drug for 
which “there is no reasonable expectation that the sales of the drug 
will be sufficient to offset the costs of developing the drug.”82 While 
critics of the Orphan Drug Act have voiced concerns about drug 
manufacturers’ abuse of orphan drug status, the Act has  contributed 
to FDA approval of important blockbuster drugs.83 Under the FDA’s 
Accelerated Approval Pathway,84 the FDA may grant priority review 
designation and orphan drug status to the same medication.85 
                                                 
77 FDA Marks Orphan Drug Law Milestone, U.S. FOOD & DRUG 
ADMIN. (last updated Oct. 24, 2017), 
https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseas
esConditions/OOPDNewsArchive/ucm333527.htm. 
78 DEP’T OF HEALTH & HUMAN SERVS., THE ORPHAN DRUG ACT: 
IMPLEMENTATION AND IMPACT 1 (2001), 
https://oig.hhs.gov/oei/reports/oei-09-00-00380.pdf. 
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79 Id. at 4 (listing the Act’s incentives as “(1) 7-year market 
exclusivity . . . (2) a tax credit of 50 percent of the cost of conducting 
human clinical trials, and (3) Federal research grants for clinical 
testing”); id. (“In 1997, Congress created an additional incentive 
when it granted companies developing orphan products an 
exemption from the usual drug application or “user” fees charged by 
the Food and Drug Administration (FDA).”); Orphan Drugs in the 




(describing additional orphan drug sponsor incentives as “some 
written recommendations provided by the FDA concerning clinical 
and preclinical studies to be completed in order to register the new 
drug” and “a fast-track procedure for the FDA to evaluate 
registration files”). 
80 Aarti Sharma, Orphan Drug: Development Trends and Strategies, 
2 J. PHARMACY & BIOALLIED SCI. 290, 290 (2010), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996062/; 
Designating an Orphan Product; Drugs and Biological Products, 
U.S. FOOD & DRUG ADMIN. (last updated Dec. 19, 2017), 
https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseas
esConditions/HowtoapplyforOrphanProductDesignation/default.htm; 
Developing Products for Rare Diseases & Conditions, U.S. FOOD & 
DRUG ADMIN. (last updated Dec. 19, 2017), 
https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseas
esConditions/ucm2005525.htm.  
25Published by Mitchell Hamline Open Access, 2018
                    CYBARIS®, AN INTELLECTUAL PROPERTY LAW REVIEW                              257 
 
                                                 
81 21 C.F.R. § 316.21(a)(1) (2013), https://www.ecfr.gov/cgi-
bin/retrieveECFR?gp=&SID=718f6fcbc20f2755bd1f5a980eb5eecd
&mc=true&n=sp21.5.316.c&r=SUBPART&ty=HTML#se21.5.316_
120 (defining the a rare disease as one “that the number of people 
affected by the disease or condition for which the drug is developed 
is less than 200,000”); Sharma, supra note 80 at 290 (“A medicinal 
product designated as an orphan drug is one that has been 
specifically developed to treat a rare medical condition, the condition 
itself being referred to as an ‘orphan disease’”). 
82 21 C.F.R. § 316(a)(2) (describing the parameters for orphan status 
regarding the drugs development to sales cost ratio in the United 
States). 
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83 James Bohan, Orphan Drugs and Why Everybody Wants One!, 
IDEA PHARMA (Mar. 15, 2017), 
http://ideapharma.com/junkie/orphan-drugs-and-why-everyone-
wants-one; Sarah Jane Tribble, Drugs for Rare Diseases Have 
Become Uncommonly Rich Monopolies, NPR (Jan. 17, 2017), 
https://www.npr.org/sections/health-
shots/2017/01/17/509506836/drugs-for-rare-diseases-have-become-
uncommonly-rich-monopolies (reporting information demonstrating 
that “the system intended to help desperate patients is being 
manipulated by drugmakers to maximize profits and to protect niche 
markets for medicines already taken by millions”); id. ( listing 
Humira, Enbrel, Remicade, and Rituxan as examples of orphan 
drugs that became blockbusters); Sarah Jane Tribble, FDA Moves to 
Rein in Drugmakers’ Abuse of Orphan Drug Law, NPR (Sept. 13, 
2017), https://www.npr.org/sections/health-
shots/2017/09/13/550700062/fda-moves-to-rein-in-drugmakers-
abuse-of-orphan-drug-law (stating that “many drugs that now have 
orphan status are not entirely new” and that the FDA “plans to close 
a loophole that allows manufacturers to skip pediatric testing 
requirements when developing a mass-market drug for treating rare 
diseases in children”). But see Walter Armstrong, Pharma’s 
Orphans, PHARMEXEC.COM (May 1, 2010), 
http://www.pharmexec.com/pharmas-orphans (“The legislation is 
almost universally viewed as a roaring success.”) 
84 Accelerated Approval, U.S. FOOD & DRUG ADMIN. (last updated 
Sept. 15, 2014), 
https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm. 
85 See Press Release FDA Approves, supra note 4 (stating that the 
treatment for Chagas disease received priority review and orphan 
status). 
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III. History of Chagas Disease Treatment 
A. Description of Chagas Disease 
Chagas disease (American Trypanosomiasis) results from the 
infection of the protozoan parasite Trypanosoma cruzi.86 Contact 
with the urine or feces of triatomine bugs infects humans.87 Infected 
insects emerge at night from their daytime hiding places in the 
cracks of walls and roofs to bite humans.88  When the person rubs or 
itches the bite area, parasite-infected feces and salvia enter the 
wound.89 Additionally, the Chagas parasite may infect patients via 
blood transfusions, contaminated food consumption, laboratory 
accidents, organ transplants, and mother-to-unborn child 
transmission.90  
                                                 
86 TINTINALLI’S EMERGENCY MEDICINE, 1102 (Judith Tintinalli, ed., 
2016). 
87Id. (indicating that triatomine bugs are also known as “kissing 
bugs” and “assassin bugs”); WHO, supra note 1. 
88 WHO, supra note 1; TINTINALLI, supra note 86 at 1102. 
89 TINTINALLI, supra note 86 at 1102; WHO, supra note 1 (stating 
that the “parasites enter the body when the person instinctively 
smears the bug feaces [sic] or urine into the bite, the eyes, the mouth, 
or any skin break”).  
90 TINTINALLI, supra note 86 at 1102; WHO, supra note 1. 
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Persons infected with the parasite first experience 
inflammation around one eye (Romaña’s sign) or painful swelling at 
the bite site.91 Chagas disease sufferers typically experience two 
phases of the illness: an acute and a chronic phase.92 During the 
acute phase, which typically lasts two to 4 weeks, infected persons 
may experience “fever, headache, enlarged lymph glands, pallor, 
muscle pain, difficulty in breathing, swelling, and abdominal or 
chest pain.”93     
After the acute phase, the untreated disease enters a latent, 
chronic stage, in which the infected person experiences few 
symptoms.94 During the chronic phase, the parasite remains dormant 
in heart, nerve, and muscle cells.95 The disease gradually destroys 
nervous and cardiac tissue, which can lead to heart disease, 
gastrointestinal malfunction, and sudden death.96 
                                                 
91 TINTINALLI, supra note 86 at 1102 (describing the swollen area 
around the bite as a “chagoma”). 
92 TINTINALLI, supra note 86 at 1102; WHO, supra note 1. 
93 TINTINALLI, supra note 9 at 1102 (noting that acute-phase may 
“last up to 3 months” and may involve high levels of the parasite in 
the blood stream, as well as swelling of the liver and spleen); WHO, 
supra note 1. 
94 TINTINALLI, supra note 86 at 1102; WHO, supra note 1; see Latent 
infection, THE FREE DICTIONARY (2017), https://medical-
dictionary.thefreedictionary.com/latent+infection (defining a latent 
infection as one that is “asymptomatic” but “capable of manifesting 
symptoms under particular circumstances,” and that “does not 
produce visible signs of a disease but may be transmitted to another 
host”). 
95  TINTINALLI, supra note 86 at 1102; WHO, supra note 1. 
96  TINTINALLI, supra note 86 at 1102 (stating that “Chagas-induced 
heart disease in the leading form of congestive heart failure in much 
of Latin America”); WHO, supra note 1. 
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Physicians diagnose acute-phase Chagas disease by taking 
blood samples or muscle biopsies.97 To diagnose Chagas disease in 
the chronic phase, physicians may utilize specialized blood tests or 
targeted organ tissue biopsies.98 
Two medications successfully kill the Trypanosoma cruzi 
protozoan—benznidazole and nifurtimox.99 These medications have 
an almost one hundred percent cure rate for patients in the acute 
phase of Chagas disease.100 However, this exceptional efficacy rate 
is only applicable if the infected person receives the medication 
“soon after infection at the onset of the acute phase.”101 The 
continued efficacy of the treatment decreases in a manner inversely 
proportional to the length of time the person has been infected.102 
Thus, the longer the delay in treatment, the less effective the 
medications are against Chagas disease.103 
                                                 
97 TINTINALLI, supra note 86 at 1102 (noting that the blood or tissue 
samples may demonstrate “motile parasites”). 
98 Id. 
99 Id. at 1102 (stating that these medications “are available in the 
United States through the Centers for Disease Control”); WHO, 
supra note 1. 
100 WHO, supra note 1 (adding that benznidazole and nifurtimox 
“are almost 100% effective in curing the disease if given soon after 
infection . . . [in] cases of congenital transmission”). 
101 Id. 
102 See id. (noting that the treatments’ efficacy also decreases with 
increased length of infection time in cases of post-natal maternal-
fetal transmission). 
103 Id.  
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No vaccine exists to prevent Chagas disease.104 Thus, 
controlling transmission through triatomine bugs, transfusions, and 
transplants is the mainstay of Chagas disease prevention.105 The 
World Health Organization’s Chagas disease prevention and control 
measures include insecticide use, improved food-preparation 
hygiene, structural home improvements, and blood donor 
screening.106 
                                                 
104 Id.  
105 Id. (explaining that “[o]riginally . . .  T. cruzi only affected wild 
animals” and that the “large reservoir of T. cruzi parasites in wild 
animals in the Americas means that the parasite cannot be 
eradicated”). 
106 WHO, supra note 1 (suggesting “spraying of houses and 
surrounding areas with residual pesticides,” repairing cracked walls 
and roofs in houses, using bednets, “testing of organ, tissue, or cell 
donors and receivers,” and “screening of newborns and other 
children of infected mothers”).  
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Chagas disease is epidemic in twenty-one Latin American 
countries, affecting between six and seven million persons 
worldwide.107 Although Chagas disease has historically been 
confined to Latin America, recent decades have seen the Chagas 
disease distribution expand to include the parts of the United States, 
Canada, Europe, and western Pacific countries.108 
                                                 
107 Id. at n.1 (listing countries with endemic areas of Chagas Disease 
as Argentina, Belize, Bolivia, Brazil, Chile, Columbia, Costa Rica, 
Ecuador, El Salvador, French Guiana, Guatemala, Guyana, 
Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Suriname, 
Uruguay, and Venezuela); Data & Statistics, CTRS. FOR DISEASE 
CONTROL & PREVENTION (last updated Oct. 25, 2017) (providing 
data for endemic-level diseases in the United States, including Lyme 
disease, tuberculosis, and viral hepatitis); Principles of Epidemiology 
in Public Health Practice, Third Edition: An Introduction to Applied 
Epidemiology and Biostatistics, CTRS. FOR DISEASE CONTROL & 
PREVENTION (last updated May 18, 2012), 
https://www.cdc.gov/ophss/csels/dsepd/ss1978/lesson1/section11.ht
ml (describing an endemic level of disease as one that is the 
“baseline” level that is the “observed  level” that is “usually present 
in a community,” and that “[i]n the absence of intervention and 
assuming that the level is not high enough to deplete the pool of 
susceptible persons, the disease may continue to occur at this level 
indefinitely”).  
108 TINTINALLI, supra note 86 at 1102 (“The protozoan Trypanosoma 
cruzi is found in up to 5% of emigrants from endemic parts of Latin 
America”); WHO, supra note 1 (stating that “Chagas disease occurs 
principally in the continental part of Latin America and not in the 
Caribbean isles” and that the spread of Chagas disease to other parts 
of the world “is due mainly to population mobility between Latin 
America and the rest of the world”).  
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B. History of Chagas Disease 
In 1908, a scientist named Carlos Justianio Ribiero de Chagas 
began dissecting “large blood-sucking insects” as part of an effort to 
combat malaria in railway construction camps in Brazil.109 Chagas 
discovered “numerous trypanosomes” in the insects and gave the 
pathogen the name Trypanosoma cruzi.110 Chagas allowed infected 
insects to bite laboratory animals and learned that “the parasite was 
infective to several . . . laboratory animals.”111 Chagas deduced that 
the trypanosomes caused an unidentified human illness.112  
                                                 
109 Dietmar Steverding, The History of Chagas Disease, U.S. NAT’L 
LIBR. MEDICINE 1, 3 (Jul. 10, 2014), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105117/ 
[hereinafter Steverding, History] (stating that Carlos Chagas (1879–
1934) was “a Brazilian hygienist and bacteriologist” who “was made 
aware by a railroad engineer of large blood-sucking insects which 
lived en masses in local dwellings and bit sleeping people 
preferentially in the face”). 
110 Id. at 3 (explaining that Chagas “named T. cruzi in honor of his 
mentor, the Brazilian physician and bacteriologist Oswaldo Cruz 
(1872–1917)); See An Introduction to Molecular Parasitology and 
Trypanosomes, ROCKEFELLER U. (last visited Dec. 20, 2017), 
http://tryps.rockefeller.edu/trypsru2_introduction.html (describing 
Trypanosomes as “microscopic unicellular protozoa that are 
ubiquitous parasites of . . . mammals” and cause diseases such as 
Chagas disease).  
111 Steverding, supra note 109 at 3–4. 
112 Id. at 4 (“Chagas was sure he had found a pathogenic organism of 
a human infectious disease but he did not know what kind of 
sickness it was.”). 
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In 1909, Chagas examined a feverish two-year old girl named 
Bernice whose spleen, liver, and lymph nodes were enlarged.113 
Although Chagas did not find T. cruzi in Bernice’s blood during his 
first examination, four days later, Chagas discovered “numerous 
trypanosomes” in her blood.114 Chagas described the illness’s acute 
phase and “linked the infection with some chronic symptoms of the 
illness.”115 Although Bernice never developed the chronic phase of 
the disease, she was infected with T. cruzi her entire life.116 
                                                 
113 Id.  
114 Id. (stating that the trypanosomes in Bernice’s blood were of 
“similar morphology” to those found in the infected laboratory 
animals’ blood). 
115 Id. (noting that Chagas’s ability to connect the two phases of the 
disease “was remarkable considering that the chronic phase of 
American trypanosomiasis usually appears decades after the first 
inoculation with T. cruzi”); Aluízio Prata, Evolution of the Clinical 
and Epidemiological Knowledge of Chagas Disease 90 Years After 
its Discovery, 94 MEMORÍAS DO INSTITUTO OSWALDO CRUZ 81, 82 
(1999), 
https://pdfs.semanticscholar.org/f513/a6c4bc9ea465663cebe3fcee39
5a92aa8631.pdf  (stating that in a preliminary note dated July 5, 
1910, Chagas “stated that there were three modalities of the disease: 
one acute and two chronic”). 
116 Steverding, History, supra note 109 at 4 (noting that Bernice died 
at the age of 73 “on unrelated causes”); See M. de Lana et al., 
Characterization of Two Isolates of Trypanosoma Cruzi Obtained 
from the Patient Bernice, the First Human Case of Chagas’ Disease 
by Carlos Chagas in 1909, 
https://www.ncbi.nlm.nih.gov/pubmed/8801560/ (“Two isolates of 
Trypanosoma cruzi were obtained from the patient Bernice . . . when 
she was 55 and 71 years old, respectively.”).  
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Although Chagas contributed significantly to the identification of 
the disease which now bears his name, other scientists played 
important roles in the description and understanding of Chagas 
disease.117 Chagas’s discovery aroused keen interest in the 
international scientific community at the time.118 Chagas received 
many international recognitions, including two Nobel Prize 
nominations.119 However, Chagas’s rapid rise to fame brought 
“animosity and envy in his own country.”120 After experiencing 
sabotaging actions from his own lab,121 scientists and colleagues 
from Brazil claimed that Chagas disease was only a local 
phenomenon and that the parasite was of “little virulence.”122 Some 
of Chagas’s opponents even accused Chagas of falsifying his 
findings and of being unpatriotic.123 Historians speculate that 
Chagas’s countrymen’s animosity toward him “may have cost 
[Chagas] the Nobel Prize.”124 Additionally, the anti-Chagas group’s 
actions likely resulted in a twenty-year period in which Chagas 
disease was all but “forgotten,” causing research and interest in the 
disease to grind to a halt.125  
                                                 
117 Prata, supra note 115 at 84 (mentioning that the Brazilian 
scientist and physician Eurico de Azevedo Villela (1883–1962) 
“always worked with Chagas”); Steverding, supra note 109 at 4 
(listing Oswaldo Cruz, the Czech zoologist and parasitologist 
Stanislaus von Prowazek (1875–1915), the Brazilian pathologist 
Gaspar de Oliveira Vianna (1885–1914), and the French pathologist 
Alexandre Joseph Émile Brumpt (1877–1951) as contributors to 
early Chagas disease research). But see Marillia Coutinho et al., The 
Noble Enigma: Chagas’ Nominations for the Nobel Prize, 94 
MEMORÍAS DO INSTITUTO OSWALDO CRUZ 123, 127 (1999),  
http://www.scielo.br/pdf/mioc/v94s1/ultimo.pdf (“Chagas had just 
performed the perfect algorithm from vector to disease within a few 
months and alone.”). 
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118 Steverding, History, supra note 109 at 5; Rachel Lewinson, 
Prophet in His Own Country: Carlos Chagas and the Nobel Prize, 
46 PERSPECTIVES IN BIOLOGY & MED. 532–40 (2003), 
http://repositorio.unicamp.br/bitstream/REPOSIP/102650/1/2-s2.0-
1542598939.pdf (stating that “Chagas’s discovery brought him 
immediate, worldwide acclaim” and that “[h]onors were showered 
upon him”);  
119 Coutinho, supra note 117 at 123 (stating that “Chagas was twice 
nominated for the Nobel Prize–in 1913 and in 1921–, [sic] but never 
received the award”); Lewinson, supra note 118.  
120 Coutinho, supra note 117 at 128 (describing the “surreptitious 
actions of the early anti-Chagas group” that led to “an unpleasant 
incident involving Rudolph Kraus, Director of the Institute of 
Bacteriology at Buenos Aires and Chagas’s own laboratory at 
Manuinhos”); Lewinson, supra note 118 (noting that “the 
overwhelming success of the young scientist from the backwoods of 
Minas Gerais set off a reaction of a different kind in some of his 
colleagues at Manguinhos, the Faculty and National Society of 
Medicine” and that “antagonism against [Chagas] . . . began to flare 
up”); Steverding, History, supra note 109 at 5.  
121 Coutinho, supra note 117at 128 (“It was clear that someone from 
Manguinhos had been feeding . . . contentions against Chagas.”); 
Lewinson, supra note 118 (describing Chagas’s reaction at finding 
slides from his own laboratory at the Institute of Bacteriology). 
122 Coutinho, supra note 117 at 128; Lewinson, supra note 118 at 
544 (listing some of Chagas’s opponent’s “preposterous 
accusations” including that the disease “was restricted to a small area 
in Minas Gerias where [Chagas] had found his first cases” and that 
“the number of cases did not exceed some 40 patients”). 
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123 Coutinho, supra note 117 at 128 (quoting the Brazilian physician 
and university president Júlio Afrânio Peixoto as saying: “You could 
have found some mosquitos, you could have invented a rare and 
unknown disease . . . a disease that you could magnanimously 
distribute among your countrymen . . . .”); Lewinson, supra note 118 
at 542 (noting that “a grotesque accusation was in store for Chagas: 
because he openly discussed the disease and its implications . . .  he 
was reproached with being unpatriotic; this stupid, pointless charge 
was to haunt him for many years.”). 
124 Coutinho, supra note 117 at 128–29 (suggesting that “it was this 
local opposition that actually prevented Chagas from being awarded 
the Nobel Prize in 1921”); Steverding, History, supra note 109 at 5.  
125 Lewinson, supra note 118 at 547–48 (quoting Chagas’s son, 
Carlos Chagas Filho, as saying that “[t]o this day, we do not know 
how many of our faculties of medicine [at the National Academy of 
Medicine in Brazil] never taught Chagas disease”); Carlos M. Morel, 
Chagas Disease, from Discovery to Control–and Beyond: History, 
Myths, and Lessons to Take Home, 94 MEMORÍAS DO INSTITUTO 
OSWALDO CRUZ 3, 4 (1999), 
http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.326.2200
&rep=rep1&type=pdf (stating that the “strong opposition against 
Chagas “had a devastating effect”); Steverding, supra note 109 at 5. 
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In the 1930s, Argentine physician and epidemiologist Salvador 
Mazza described thousands of cases of Chagas disease in 
Argentina.126 In 1935, Cecilio Romaña described the periorbital 
swelling that is commonly present in Chagas disease patients during 
the acute phase of the illness.127 Because Romaña’s sign was so 
distinctive, the number of reported cases of Chagas disease increased 
dramatically after 1935.128 By 1940, thousands of cases of Chagas 
disease had been diagnosed.129 
                                                 
126 Morel, supra note 125 at 4 (stating that “[t]he ‘resurrection’ of 
Chagas disease is mainly due to the work of Salvador Mazza in 
Argentina” and noting that Mazza was “the first one to raise the 
possibility of transfusion-transmitted Chagas disease”); Prata, supra 
note 115 at 85 (stating that “under the guidance of Mazza, the 
reports . . . started to appear, with many acute cases also detected, 
especially in Chile and Uruguay”); Steverding, History, supra note 
109 at 5. 
127 What is Chagas disease?, CTRS. FOR DISEASE CONTROL & 
PREVENTION (last updated Dec. 19, 2017), 
https://www.cdc.gov/parasites/chagas/gen_info/detailed.html 
(describing Romaña’s sign as “the most recognized marker of acute 
Chagas disease”). 
128 Prata, supra note 115 at 85 (noting that Ezequiel Dias and 
Evandro Chagas (Carlos Chagas’s son) considered the “discovery of 
the Romaña sign” to be “the most valuable foreign contribution to 
the disease” and that “thanks to the Romaña sign [sic] which permits 
suspecting the disease at a distance, more than 500 cases were 
detected in Argentina and about 100 in Uruguay” between 1934 and 
1938) 
129 François Delaporte, Romana’s Sign, 30 J. HISTORY BIOLOGY 357, 
357 (1997), 
https://link.springer.com/article/10.1023/A%3A1004221722554  
(“Once thought to be a provincial affliction limited to the state of 
Minas Geres, Chagas disease was now seen to be an endemic malady 
throughout Latin America.”). 
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C. Development of Chagas Disease Treatments 
 In the years following his description of Chagas disease, 
researchers attempted to find a treatment for Chagas disease.130 
These efforts were unsuccessful, leading Chagas and his son 
Evandro to state in 1935 that “there was no specific treatment” for 
Chagas disease.131 Between 1912 and 1962, researchers 
experimented with a variety of chemical agents in their endeavors to 
find a treatment for Chagas disease.132 Beginning in 1918, 
researchers employed various methods to obtain vector control of the 
Chagas disease-transmitting insect.133 
                                                 
130 José Rodrigues Coura & Solange L. de Castro, A Critical Review 
on Chagas Disease Chemotherapy, 97 MEMORÍAS DO INSTITUTO 
OSWALDO CRUZ 3, 4 (2002),  
http://www.scielo.br/pdf/mioc/v97n1/review.pdf (stating that in 
1912 and 1914, Mayer and Rocha Lima experimented with several 
agents, including arsenical, rosanilin dye, antimony potassium, and 
mercury chloride); Steverding, History, supra note 109 at 5. 
131 Coura & Castro, supra note 130 at 4 (stating that Carlos and 
Evandro Chagas reported that “[d]rugs with trypanocidal activity 
have been assayed by a great number of researchers, but without 
success”); Steverding, History, supra note 109 at 5. 
132 Coura & Castro, supra note 130 at 4 (listing some of the 
“chemotherapeutic agents employed until 1962,” including quinolein 
derivatives, bismuth, gentian violet, nicotinic acid hydrazide, 
cortisone, and “more than 30 antibiotics and some nitrofurans”).  
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133 WORLD HEALTH ORG., HANDBOOK FOR INTEGRATED VECTOR 
MANAGEMENT 1 n.1 (2012), 
http://apps.who.int/iris/bitstream/10665/44768/1/9789241502801_en
g.pdf (“ ‘Vector-borne disease’ is the collective term for infectious 
diseases transmitted by insects, snails, or rodents, which act as 
vectors of the actual pathogens.”); João Carlos Pintos Dias, The 
Beginning of Chagas Disease Control (Homage to Dr. Emmanuel 
Dias, the pioneer of Chagas Disease Control, in the Year of His 
Birth Centenary), 44 REVISTA DA SOCIEDADE BRASILEIRA DE 
MEDICINA TROPICAL 12, 12 (2011), 
http://www.scielo.br/pdf/rsbmt/v44s2/a03v44s2.pdf (listing housing 
improvements, DDT, fire throwers, and cyanidric gas as agents used 
in early attempts at Chagas disease vector control). 
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1. Nifurtimox 
 The first drugs to demonstrate efficacy against Chagas 
disease were those belonging to the nitrofuran class.134 The Eaton 
laboratory marketed a type of nitrofuran called nitrofurazone in 
Brazil.135 In the 1967, the Bayer pharmaceutical company introduced 
the empirically-discovered drug nifurtimox to treat Chagas disease 
under the trade name Lampit.136 In 1997, Bayer ceased production of 
nifurtimox due to “lack of profitability.”137However, in 2000, Bayer 
recommenced nifurtimox production as part of the treatment of 
African sleeping sickness.138 In 2004, Bayer agreed to provide the 
World Health Organization 500,000 tablets a year at no cost.139 In 
2011, Bayer increased this amount to one million tablets a year, 
making this “donated drug . . . the primary source of nifurtimox 
worldwide.”140 Nifurtimox is not FDA approved for distribution in 
the United States, but the Centers for Disease Control (CDC) 
dispenses the drug under its Expanded Access program.141 
                                                 
134 José Rodrigrues Coura, Present Situation and New Strategies for 
Chagas Disease Chemotherapy—A Proposal, 104 MEMORÍAS DO 
INSTITUTO OSWALDO CRUZ 549, 549 (2009), 
http://www.scielo.br/pdf/mioc/v104n4/02.pdf; Nitrofurans, GOLD 
BIO (last visited Dec. 21, 2017), 
https://www.goldbio.com/category/nitrofurans (Nitrofurans are a 
class of drugs typically used as antibiotics or antimicrobials. The 
defining structural component is a furan ring with a nitro group.”); 
Steven Perez, Nitrofuran Analyses (FAQ), ADPEN LABORATORIES, 
INC. (May 26, 2010), http://adpen.com/2010/05/nitrofurans/ 
(“Nitrofurans are a class of drugs that have the ability to kill micro-
organisms [sic].”). 
135 Coura, supra note 134 at 550 (noting that the drug was sold in 
Brazil “as Furacin ointment for topical use”). 
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136 Johathan D. Alpern et al., Access to Benznidazole for Chagas 
Disease in the United States—Cautious Optimism?, PLOS 
NEGLECTED TROPICAL DISEASES 1, 3 (2017), 
http://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.
0005794&type=printable; Riza Theresa Bautista-Navarro, Drug 
Discovery, ENCYCLOPEDIA SYSS. BIOLOGY, 
https://link.springer.com/referenceworkentry/10.1007%2F978-1-
4419-9863-7_1340 (last visited Dec. 21, 2017),  (“Empirical drug 
discovery involves finding a compound that produces a desired 
therapeutic effect in vitro. Initially, there is no understanding of the 
candidate drug’s mechanism of action.”); Dietmar Steverding, The 
Development of Drugs for Treatment of Sleeping Sickness, 3 
PARASITES & VECTORS 1, 5 (2010), 
https://parasitesandvectors.biomedcentral.com/track/pdf/10.1186/17
56-3305-3-15?site=parasitesandvectors.biomedcentral.com 
[hereinafter Steverding, Development]. 
137 Alpern, supra note 136 at 3; see also Coura & Castro, supra note 
130 at 5 (“Since the 1980s, [nifurtimox] had its commercialization 
discontinued, first in Brazil, and then in Chile, Argentina, and 
Uruguay.”). But see Steverding, History, supra note 109 at 5 (stating 
that “the production of nifurtimox was suspended in 1997 due to 
lack of demand”). 
138 Steverding, Development, supra note 136 at 5 (explaining that 
nifurtimox has shown success in treating a form of late-stage African 
sleeping sickness when combined with eflornithine); Steverding, 
History, supra note 109 at 5.  
139 Alpern, supra note 136 at 3; Colin J. Forsyth et al., Safety Profile 
of Nifurtimox for Treatment of Chagas Disease in the United States, 
63 CLINICAL INFECTIOUS DISEASES 1056, 1061 (2016), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036918/pdf/ciw47
7.pdf ;  
140 Alpern, supra note 136 at 3; Forsyth, supra note 139 at 1061. 
42https://open.mitchellhamline.edu/cybaris/vol9/iss2/3
                    CYBARIS®, AN INTELLECTUAL PROPERTY LAW REVIEW                              274 
 
                                                 
141 Alpern, supra note 136 at 3; Antiparasitic Treatment, CDC (last 
updated Aug. 31, 2017), 
https://www.cdc.gov/parasites/chagas/health_professionals/tx.html 
(stating that nifurtimox is “currently available under investigational 
protocols from the CDC”); Expanded Access (Compassionate Use), 
U.S. FOOD & DRUG ADMIN. (last updated Oct. 3, 2017), 
https://www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAcce
ssCompassionateUse/default.htm (explaining that expanded access 
“is the use outside of a clinical trial of an investigational medical 
product”). 
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2. Benznidazole 
 1966, the pharmaceutical company Hoffman La-Roche 
developed the drug benznidazole.142 In 1971, Roche began 
marketing the drug in several South American countries under the 
names Rochagan, Radanil, and Ragonil.143 In 2003, Roche 
transferred its rights to benznidazole to the Brazilian government.144 
Roche and Brazil then agreed to subcontract the marketing and 
production of benznidazole to “a public Brazilian agency” called the 
Laboratorio Farmaceutico do Estado de Pernambuco (LAFEPE).145 
In August 2004, Roche delivered an adequate amount of the active 
ingredient in benznidazole for LAFEPE to register the drug with the 
Brazilian Drug Regulatory Authority (ANVISA).146 In November 
2006, ANVISA authorized LAFEPE to market benznidazole in 
Brazil.147 Roche then withdrew its registration for benznidazole, 
leaving LAFEPE as the sole manufacturer of benznidazole in the 
world.148 
                                                 
142 Steverding, History, supra note 109 at 5.  
143 SUMMARY REVIEW: NDA 209570 BENZNIDAZOLE, CTR. DRUG 
EVALUATION & RES. 8 (2016), 
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209570O
rig1s000SumR.pdf [hereinafter SUMMARY REVIEW] (stating that 
“Roche obtained registration of [benznidazole] in Brazil, Argentina, 
Bolivia, Uruguay, Peru, and Nicaragua”). 
144 SUMMARY REVIEW, supra note 143 at 8; Shortage of 
Benznidazole Leaves Thousands of Chagas Patients Without 
Treatment, MÉDECINS SANS FRONTIÈRES (Oct. 1, 2011), 
http://www.doctorswithoutborders.org/news-stories/briefing-
document/shortage-benznidazole-leaves-thousands-chagas-patients-
without (explaining that Roche “transferred the manufacturing 
technology and the license to produce to Brazil’s Pernambuco 
state”); Critical Shortage of First-Line Therapy for Chagas: The 
Story of Benznidalzole, MÉDECINS SANS FRONTIÈRES ACCESS 
CAMPAIGN (last updated Apr. 10, 2012), 
https://www.msfaccess.org/content/critical-shortage-first-line-
therapy-chagas-story-benznidazole [hereinafter MSF Critical]. 
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145 Briefing Document, Médecins Sans Frontières, The Shortage of 
Benznidazole Leaves Thousands of Chagas Patients Without 
Treatment 1 (Oct. 2011), 
http://www.doctorswithoutborders.org/sites/usa/files/Chagas%20brie
fing%20paper%20Final.pdf [ hereinafter MSF Briefing Document); 
see SUMMARY REVIEW, supra note 143 at 8.  
146 MSF Briefing Document, supra note 145 at 1 (giving the 
Brazilian name of ANVISA as Agência Nacional de Vigilância 
Sanitária); see SUMMARY REVIEW, supra note 143 at 8.  
147 MSF Briefing Document, supra note 145 at 1; SUMMARY 
REVIEW, supra note 143 at 8.  
148 Alpern, supra note 136 at 2; MSF Critical, supra note 144; MSF 
Briefing Document, supra note 145 at 1–2 (adding that “products 
previously produced by Roche continued to be available until their 
expiration date, with stocks available up to October 2010”); 
SUMMARY REVIEW, supra note 143 at 8. 
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 Because Roche was no longer producing benznidazole, 
LAFEPE need to obtain a source of the drug’s active pharmaceutical 
ingredient (“API”).149 By 2010, Roche had provided the necessary 
documentation to allow a company called Nortec Química to 
manufacture benznidazole’s API.150 Although a manufacturer and an 
API supplier were now in place, various administrative problems 
arose that created a delay in benznidazole production.151 
                                                 
149 MSF Briefing Document, supra note 145 at 2; Kathlyn Stone, 
What Is an Active Pharmaceutical Ingredient (API)?, THE BALANCE 
(last updated June 20, 2017), https://www.thebalance.com/api-
active-pharmaceutical-ingredient-2663020 (explaining that an API 
“is the part of any drug that produces its effects” and that some drugs 
“have multiple active ingredients”). 
150 MSF Briefing Document, supra note 145 at 2.  
151 Alpern, supra note 136 at 2 (describing the reasons for the 
ensuing worldwide benznidazole shortage as “multifactorial”); MSF 
Critical, supra note 144 (stating that there was “a lack of 
coordination between the API supplier Nortec, LAFEPE and the 
Brazilian Ministry of Health”);  
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 Meanwhile, the need for benznidazole was increasing.152 
This increasing demand arose from various factors.153 First, evidence 
had recently demonstrated that benznidazole was effective in treating 
Chagas disease patients in the chronic stage.154 Previously, 
researchers believed that the drug was only able to treat the acute 
form of Chagas disease.155 Second, recent research indicated that 
patients up to age 60 could benefit from benznidazole treatment.156 
Formerly, concerns about the safety to administering benznidazoleto 
adults had limited the drug’s use in older patients.157 These changes 
in prescribing recommendations expanded benznidazole’s use to 
treat chronic Chagas disease patients and older patients.158 
                                                 
152 Alpern, supra note 136 at 2; MSF Briefing Document, supra note 
145 at 2.  
153 See MSF Briefing Document, supra note 145 at 2 (“Clear signs 
showed that the demand for benznidazole was set to increase.”). 
154 Alejandro M. Hasslocher-Moreno et al., Safety of Benznidazole 
Use in the Treatment of Chronic Chagas Disease, 67 J. 
ANTIMICROBIAL CHEMOTHERAPY 1261, 1261 (2012), 
https://academic.oup.com/jac/article/67/5/1261/980974 (noting in 
2012 that “[d]espite the controversy over the efficacy of 
[benznidazole] treatment for adult patients in the chronic phase” that 
“some centres advocate using [benznidazole] in order to reduce the 
morbidity and mortality of the disease” and that benznidazole was 
“recommended for all cases of acute, congenital, reactivated, and 
chronic Chagas disease in children under 12 years of age”); MSF 
Briefing Document, supra note 145 at 2.  
155 Coura & Castro, supra note 130 at 5 (noting in 2002 that “[i]n 
relation to chronic [Chagas disease] cases, results [using 
benznidazole] have been poor”); MSF Briefing Document, supra 
note 145 at 2 (“Initially, treatment with benznidazole was intended 
only for people in the acute phase of the disease.”); Steverding, 
History, supra note 109 at 5 (stating that originally, benznidazole 
was “primarily used for treatment of acute cases of Chagas disease 
because [it]was considered less effective in the chronic phase”). 
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156 MSF Briefing Document, supra note 145 at 2. Compare Maria-
Jesús Pinazo et al., Tolerance of Benznidazole in Treatment of 
Chagas’ Disease in Adults, ANTIMICROBIAL AGENTS & 
CHEMOTHERAPY 4896, 4896 (2010), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2976114/pdf/0537-
10.pdf (finding in 2010 that “ the unwanted side effects [of 
benznidazole] are more frequent and severe in adults than in 
children”), with  Hasslocher-Moreno, supra note 154 at 1265 
(finding in 2012 that “[t]reatment with benznidazole was considered 
safe” for Chagas disease patients up to 65 years old).  
157 MSF Briefing Document, supra note 145 at 2; Pinazo, supra note 
156 at 4896 (noting in 2010 that “[i]n adults, benznidazole has a 
high rate of adverse effects”). 
158 Oliver Yun et al., Feasibility, Drug Safety, and Effectiveness in 
Etiological Treatment Programs for Chagas Disease in Honduras, 
Guatemala, and Bolivia; 10-Year Experience of Médecins Sans 
Frontières, 3 PLOS NEGLECTED TROPICAL DISEASES 1, 7–8 (2009), 
https://www.ncbi. 
m.nih.gov/pmc/articles/PMC2700957/pdf/pntd.0000488.pdf (“Over 
the past decade, treatment for Chagas disease has expanded from 
children <12 years old, to < 15, then to <18, and finally adults.”);  
MSF Briefing Document, supra note 145 at 2; see R. Viotti et al., 
Towards a Paradigm Shift in the Treatment of Chronic Chagas 
Disease, 58 ANTIMICROBIAL AGENTS & CHEMOTHERAPY 635, 635 
(2014), http://aac.asm.org/content/58/2/635.full.pdf+html (reviewing 
“the paradigm shift” and “argu[ing] in favor of antiparasitic 
treatment for all chronic [Chagas disease] patients”). 
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 Concurrent with the expansion of benznidazole’s 
recommended use, various agencies “launched campaigns to raise 
awareness of Chagas disease.”159 Médecins Sans Frontières 
(MSF),160 the Drugs for Neglected Disease Initiative (DNDi),161 the 
World Health Organization (WHO), and the Pan American Health 
Organization (PAHO) set forth guidelines or passed resolutions 
concerning Chagas disease awareness, diagnosis, and “demand 
forecasting” for benznidazole.162 The combination of expanding 
prescribing recommendations and increasing international concern 
about Chagas disease led to increased demands on the world’s single 
supplier of benznidazole.163 In 2011, when LAPEFE was unable to 
fill orders for benznidazole, a “global shortage ensued.”164  
                                                 
159 MSF Briefing Document, supra note 145 at 2.  
160 About MSF, MÉDECINS SANS FRONTIÈRES (last visited Dec. 22, 
2017), http://www.msf.org/en/about-msf. 
161 Neglected Patients, DRUGS FOR NEGLECTED DISEASES INST. (last 
visited Dec. 22, 2017), https://www.dndi.org/.  
162 Chagas R&D Accelerator Initiative, World Health Organization ¶ 
13 (2009), 
http://www.who.int/phi/implementation/chagas_R_D_accelerator_in
itiative.pdf  (describing “demand forecasting” as estimating “Chagas 
treatment needs of endemic countries”); MSF Briefing Document, 
supra note 145 at 2; MSF Critical, supra note 144 (stating that the 
“demand forecasting tool has been created to estimate demand for 
benznidazole”); see Neglected Infectious Diseases and Other 
Poverty-Related Diseases in the Americas, PAHO (last visited Dec. 
22, 2017), http://www.paho.org/pahobranding/wp-
content/uploads/2013/08/NCD_Opt1_v1.pdf (providing public 
information about NTDs—including Chagas disease—based on a 
resolution from the 2009 Directing Council of PAHO). 
163 MSF Briefing Document, supra note 145 at 2. 
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164 Alpern, supra note 136 at 2 (“In 2011, a [benznidazole] shortage 
occurred in the face of increased demand due to improved 
recognition and screening efforts worldwide.”); MSF Briefing 
Document, supra note 145 at 2; MSF Critical, supra note 144; see 
Miriam Navarro et al., Short Report; Benznidazole Shortage Makes 
Chagas Disease a Neglected Tropical Disease in Developed 
Countries; Data from Spain, 87 AM. J. TROPICAL MED. & HYGIENE  
489, 489 (2012), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3435352/pdf/tropm
ed-87-489.pdf   (“The current shortage of benznidazole makes 
Chagas disease a neglected tropical disease also in developed 
countries.”).  
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 The benznidazole shortage affected several countries, 
including developed countries such as Spain.165 Many traditionally 
Chagas-endemic countries suffered significant deficits of 
benznidazole during this time.166 Additionally, global migration 
from Chagas-endemic areas brought new cases of Chagas disease to  
regions such as Europe and the United States.167 These areas 
suddenly needed a drug no one seemed to have.168 
                                                 
165 Alpern, supra note 136 at 2; Navarro, supra note 164 at 489 
(stating that [i]n Spain alone, at least 5,003,460 benzinadazole 
tablets [were] needed” and that “more than 23,000 [would] not 
receive the treatment they need[ed]”).  
166 Press Release, Médecins Sans Frontières, Treatment Ends for 
Chagas Patients (Oct. 5, 2011), https://www.msfaccess.org/about-
us/media-room/press-releases/treatment-ends-chagas-patients 
[hereinafter Press Release] (stating that Chagas disease in “endemic 
in several Latin American countries” and that the shortage of 
benznidazole was creating situations that were “not acceptable” in 
Brazil, Bolivia, and Paraguay); MSF Briefing Document, supra note 
145 at 4 (stating that in 2011, LAFEPE “informed MSF” that 
LAFEPE would be unable to fill MSF’s orders for benznidazole in 
Boliva, Paraguay, and Columbia). 
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 Some relief arrived in 2012, when an Argentine company, 
Maprimed, became a benznidazole API supplier to an Argentine 
pharmaceutical company, ELEA.169 ELEA distributed its 
benznidazole product, Abrax, to Latin American countries, including 
Bolivia, Paraguay, Chile, and Argentina.170 Currently, LAPEFE and 
ELEA are the only sources of benznidazole in the world. 
                                                 
167 Mauizio Bonati & Valeria M. Confalonieri, Global Rights for 
Global Diseases: The Shortage of Benznidazole Case, 22 EUR. J. 
PUB. HEALTH (2012), 
https://academic.oup.com/eurpub/article/doi/10.1093/eurpub/el_316/
2547684 (noting that “as a result of migration and travel from [Latin 
America], [Chagas disease] is now also present in non endemic [sic] 
countries, including those in many European regions (in Belgium, 
France, Italy, Spain, Switzerland, the United Kingdom)”); Press 
Release, supra note 166 (stating that “Chagas disease . . .  is a highly 
important but little-addressed public health issue, not only in Latin 
America but also increasingly in non-endemic, developed countries, 
due to globalization and population flows”); see Navarro, supra note 
164 at 489–90 (stating that Bolivia has the “highest [Chagas] disease 
burden in the world” and that in 2011, 206,635 registered migrants 
from Bolivia lived in Spain—25,080 of whom were adults infected 
with T. cruzi). 
168 See Bonati & Confalonieri, supra note 167 (“Such an illogical 
situation, in which lifesaving treatment for millions of people 
depends wholly on a single pharmaceutical company . . .  should 
make everyone think.”). 
169 SUMMARY REVIEW, supra note 143 at 8; Alpern, supra note 136 
at 2–3.  
170 SUMMARY REVIEW, supra note 143 at 8 (noting that Abrax “is 
also available in Spain”); Alpern, supra note 136 at 3.  
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III. The Road to FDA Approval 
 On August 20, 2015, the FDA set forth an order describing 
the criteria by which a disease may be added to the list of NTD 
eligible for a PRV.171 The Food, Drug, and Cosmetic (FD&C) Act 
originally contained a list of sixteen tropical diseases for which the 
FDA could grant a PRV.172 Section 524 of the FD&C Act provided 
the authority under which the FDA could designate another tropical 
disease as PRV-eligible.173 The FDA’s order also “opened a docket 
to receive recommendations from the public for future additions to 
the list.”174 Additionally, the FDA order added Chagas disease and 
neurocysticercosis to the list of NTDs in the FD&C Act.175 
                                                 
171 21 U.S.C. § 360n (2008), https://www.kidsvcancer.org/wp-
content/uploads/2008/05/FDCActChapter-V_DrugsandDevices-
Priority-Review-to-Encourage-Treatments-for-Tropical-
Diseases.pdf; Designating Additions to the Current List of Tropical 





172 21 U.S.C. § 360n (2008); Ridley, Priority Review Vouchers, 
supra note 21; cf. 21 U.S.C. § 360n (2017) (including Filovirus 
diseases and Zika virus diseases on the list of NTDs, both of which 
legislation added in 2014). 
173 21 U.S.C § 360n(a)(3)(S) (“Any other infectious disease for 
which there is no significant market in developed nations and that 
disproportionately affects poor and marginalized populations, 
designated by order of the Secretary.”); 21 C.F.R. § 317; TDPRV 
GUIDANCE, supra note 67 at 4.  
174 21 C.F.R. § 317; TDPRV GUIDANCE, supra note 67 at 4.  
175 21 C.F.R. § 317; TDPRV GUIDANCE, supra note 67 at 4; Ridley, 
Priority Review Vouchers, supra note 21. 
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A. The Race for the Benznidazole PRV 
 Once the FDA added Chagas disease to list its list of NTD, 
interest in acquiring FDA approval for benznidazole soared.176 In 
November 2015, Martin Shkreli, former hedge fund manager and 
founder of Turing Pharmaceuticals, became CEO of the California 
biotechnology company KaloBios.177 On December 3, 2015, 
KaloBios announced its purchase of the rights to benznidazole from 
Savant Neglected Diseases.178 In a press release, KaloBios stated its 
intent to “file for Orphan Drug Designation and Fast Track 
Designation for benznidazole in Chagas Disease.”179 Additionally, 
KaloBios expected to receive a PRV if the FDA approved 
benzndazole.180  
                                                 
176 JEREMY BAROFSKY & JAKE SCHNEIDER ,  PROMOTING PRIVATE 
SECTOR INVOLVEMENT IN NEGLECTED TROPICAL DISEASE RESEARCH 
AND DEVELOPMENT 11 (2017), https://www.brookings.edu/wp-
content/uploads/2017/12/br_health4_optimized_final.pdf 
(“Following the addition of Chagas disease to the list of PRV 
eligible conditions, market activities for Chagas disease increased 
substantially.”); Courtney Columbus, Drug for ‘Neglected’ Chagas 
Disease Gains FDA Approval Amid Price Worries, NPR (Sept. 10, 
2017), https://www.npr.org/sections/health-
shots/2017/09/10/547351794/drug-for-neglected-chagas-disease-
gains-fda-approval-amid-price-worries (explaining that benznidazole 
was “the best of the two available options for treating Chagas” 
because benznidazole is “more toxic” than nifurtimox); id. (referring 
to a PRV as a “potential gold mine” and a “golden ticket” for 
pharmaceutical companies); Daisy Hernández, A New Strategy to 
Undermine Big Pharma’s Price Gouging Actually Worked, SLATE 
(Sept. 7, 2017), 
http://www.slate.com/articles/health_and_science/medical_examiner
/2017/09/inside_the_battle_to_approve_a_chagas_treatment.html 
(stating that “[w]ith its inclusion on that federal list in 2015, Chagas 
became a cash cow in the pharma world”). 
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177 Damian Garde, Shkreli’s KaloBio Buys an Old Drug with Eyes on 
a Lucrative FDAVoucher, FIERCE BIOTECH (Dec. 4, 2015), 
https://www.fiercebiotech.com/financials/shkreli-s-kalobios-buys-
an-old-drug-eyes-on-a-lucrative-fda-voucher (describing KaloBios 
as “a once-doomed company brought back from the brink by biotech 
entrepreneur Martin Shkreli”); David Goldman, Who is Martin 
Shkreli? A Timeline, CNN MONEY (Dec. 18, 2015), 
http://money.cnn.com/2015/12/18/news/companies/martin-
shkreli/index.html (“Shkreli formed Turing Pharmaceuticals in 
February 2015, which bought the rights to Daraprim, a 
toxoplasmosis treatment used by AIDS patients.”); see id. (“Turing 
caught fire in September 2015 for hiking the price of Daraprim. A 
single pill, which had cost $13, was raised 5,000% to $750.”); 
Andrew Pollack, Drug Goes From $13.50 a Tablet to $750, 
Overnight, N.Y. TIMES (Sept. 20, 2015), 
https://www.nytimes.com/2015/09/21/business/a-huge-overnight-
increase-in-a-drugs-price-raises-protests.html. 
178 Press Release, KaloBios, KaloBios Announces Agreement to 
Acquire Benznidazole Program for the Treatment of Chagas Disease 
(Dec. 3, 2015), https://ir.humanigen.com/press-
releases/detail/71/kalobios-announces-agreement-to-acquire-
benznidazole [hereinafter KaloBio Press Release] (stating that 
KaloBios was to pay Savant “an upfront payment of $ 2 million, plus 
regulatory milestones and a royalty based  on sales”). 
179 Id.; Garde, supra note 177 (“KaloBios plans to file to the FDA’s 
fast-track designation in hopes of scoring a quick approval for 
benznidazole without running any clinical trials of its own.”). 
180 KaloBios Press Release, supra note 178; Garde, supra note 177 
(“And, because [Chagas disease] is on the FDA’s list of neglected 
tropical ailments, winning approval would grant KaloBios a 
tradeable coupon that shortens drug reviews by four months.”). 
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 After forming the agreement with Savant, Shkreli told 
KaloBios investors that the price of benznidazole would be similar to 
the price of hepatitis C drugs.181 KaloBios’s price for benznidazole 
would have cost Chagas disease patients between $60,000 and 
$100,000 per treatment.182 On December 17, 2015, the FBI arrested 
KaloBios CEO Martin Shkreli on securities fraud charges.183 That 
same day, KaloBios fired Shkreli.184 The value of KaloBios’s stock 
plunged after news of Shkreli’s arrest became public.185 However, 
KaloBios continued to pursue FDA approval of benznidazole 
following Shkreli’s dismissal.186 
                                                 
181 Laura Bult, Martin Skhreli Plans to Raise Price of Drug for 
Parasitic Infection Chagas Disease, N.Y. DAILY NEWS (stating that 
during a public conference call with investors “Shkreli gleefully 
announced the purchase of the Chagas treatment  and said that he 
would price the drug, benzinidazole, similarly to hepatitis C drugs”); 
Andrew Pollack, Martin Shkreli’s Latest Plan to Sharply Raise Drug 
Price Prompts Outcry, N.Y. TIMES (Dec. 11, 2015), 
https://www.nytimes.com/2015/12/12/business/martin-shkrelis-
latest-plan-to-sharply-raise-drug-price-prompts-
outcry.html?mcubz=3 [hereinafter Pollack Outcry]; see Forward 
Looking Statements, KaloBios Pharmaceuticals (Dec. 2015), 
https://www.sec.gov/Archives/edgar/data/1293310/00011046591508
2792/a15-24519_1ex99d1.htm (stating under the heading 
“Commercial Opportunities” that benznidazole “[p]ricing expected 
to be similar to Hepatitis C antivirals”). 
182 Pollack Outcry, supra note 181. 
183 Chris Isidore & Aaron Smith, Reviled Drug CEO Martin Shkreli 
Arrested, CNN MONEY (Dec. 18, 2015), 
http://money.cnn.com/2015/12/17/news/companies/martin-shkreli-
arrest-reports/index.html (noting that the federal case against Shkreli 
“center[ed] on his time as CEO of Retrophin, . . . another biotech 
company that ousted him last year”). 
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184 KaloBios Fires Shkreli as CEO, REUTERS (Dec. 21, 2015), 
https://www.reuters.com/article/us-usa-crime-shkreli/kalobios-fires-
shkreli-as-ceo-idUSKBN0U41R720151221.  
185 Laura Lorenzetti, KaloBios Just Fired Martin Shkreli as CEO, 
FORTUNE (Dec. 21, 2015), http://fortune.com/2015/12/21/martin-
shkreli-kalobios/.  
186 See BRIEF—KaloBios to Have FDA Meeting for Using 
Benznidazole for Treating Chagas Disease, REUTERS (Dec. 5, 2016), 
https://www.reuters.com/article/idUSFWN1E00AT [hereinafter 
BRIEF]; Beth Mole, In Comeback Bid, Shkreli’s Old Company Gets 
OK to Buy Life-Saving Drug, ARS TECHNICA (Feb. 27, 2016), 
https://arstechnica.com/science/2016/02/in-comeback-bid-shkrelis-
old-company-gets-ok-to-buy-life-saving-drug/ (stating that a 
Delaware bankruptcy court authorized KaloBios to continue its 
purchase of benznidazole rights from Savant). 
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 The U.S. and international medical communites reacted to 
KaloBios’s possible price-jacking of benznidazole with considerable 
concern and apprehension.187 The price of benznidazole in many 
Chagas disease-endemic countries was $50 to $100 per treatment.188 
Further, the CDC had been dispensing benznidazole at no cost to 
patients participating in investigational protocols.189 To allow 
KaloBios to obtain FDA approval of benznidazole and then 
drastically raise its price was unacceptable to public health care 
advocates.190 Consequently, two non-profit groups and a 
pharmaceutical company formed a partnership and “set out . . . to 
register the drug where its [sic] needed, including the U.S.”191  
                                                 
187 Press Release, Drugs for Neglected Diseases initiative, DNDi 
statement on KaloBios’ [sic] Intention to Raise Price of Chagas Drug 
and File for FDA Priority Review (Dec. 14, 2015), 
https://www.dndi.org/2015/media-centre/press-releases/dndi-
statement-on-kalobios-intention-to-raise-price-of-chagas-drug-and-
file-for-fda-priority-review-2/ [hereinafter Press Release DNDi] 
(quoting Dr. Bernard Pécoul, Executive Director of Drugs for 
Neglected Diseases initiative (DNDi) as saying that “[a]t this point, 
we see the move by KaloBios as a direct threat to affordable 
benznidazole both in the U.S. and in Latin America”); Mole, supra 
note 186 (“When KaloBios and Shkreli first revealed the plan late 
last year, it sparked public outcry from public health experts and 
infectious disease doctors who feared that the new cost would make 
it difficult for the millions of patients in Central and South America 
to get the drug.”); Pollack Outcry, supra note 181 (“ ‘It’s caused a 
lot of angst in the Chagas community,’ said Dr. Sheba Meymandi . . 
. .‘Everyone’s in an uproar.’ ”). 
188 Press Release DNDi, supra note 187; Pollack Outcry, supra note 
181. 
189 Alpern, supra note 136 at 3; Pollack Outcry, supra note 181. But 
see Hernández, supra note 176 (noting that “between 2007 and 2013 
the [CDC] only released 422 doses of both benznidazole and 
[nifutimox]”). 
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190 See Press Release DNDi, supra note 187 (“We could face a 
nightmare situation for Chagas patients and healthcare providers in 
the US: the drug will finally be registered, but it could be even less 
accessible than it is today.”); Hernández, supra note 176 (“What 
Shkrelu didn’t count on were the people—physicians and 
advocates—who would be outraged over his tatics.”); DNDi, Mundo 
Sano, and Chemo Team Up to Register Benznidazole in US and 
Latin America, INSUD PHARMA (June 9, 2016), 
http://www.insudpharma.com/dndi-mundo-sano-and-chemo-team-
register-benznidazole-us-and-latin-america [hereinafter DNDi, 
Mundo Sano, and Chemo] (quoting DNDi’s Executive Director as 
saying: “Our ambition is to put an end to a scandalous and 
unjustifiable situation where almost none of the people living with 
Chagas has access to existing treatments”).  
191 John Carroll, A Non-Profit Group’s Chagas Drug Beat Out 
Martin Shkreli’s Old Rival to FDA OK, Valuable PRV, ENDPOINT 
NEWS (Aug. 30, 2017), https://endpts.com/fda-oks-nonprofit-groups-
old-chagas-drug-handing-out-prv-and-clearing-way-to-cheap-price/; 
DNDi, Mundo Sano, and Chemo, supra note 190 (describing DNDi 
as a “non-profit drug development organisation [sic],” Mundo Sano 
as a “non-profit foundation,” and Chemo Group as a 
“pharmaceutical company” that is a “corporate responsibility 
partner” with Mundo Sano, and stating that the trio “are entering into 
a formal collaboration to boost affordable access to benznidazole”). 
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 In June 2106, Drugs for Neglected Diseases initiative 
(DNDi), Mundo Sano, and Chemo Group entered into formal 
agreements to provide benznidazole to the 300,000 Chagas disease 
patients in the United States.192 The team also hoped to increase the 
worldwide availability of benznidazole while maintaining the drug’s 
attainable cost.193 Chemo Group sought to gain FDA approval for 
benznidazole in 2013— before the FDA added Chagas disease 
treatments to the list of PRV eligible drugs.194 In the agreement with 
Mundo Sano, DNDi committed to providing research data and 
support.195 Additionally, Chemo Group would give Mundo Sano half 
of “any PRV-related financing” if Chemo Group secured a PRV.196 
The agreement then stipulated that “DNDi and Mundo Sano would 
manage jointly those funds” to support non-profit activities 
benefitting Chagas disease patients.197 Moreover, Chemo Group 
agreed to provide benznidazole “on an affordable basis.”198 
                                                 
192 DNDi, Mundo Sano, and Chemo, supra note 190; (calling the 
group’s effort a “bid to overturn a situation where less than 1% of 
people with Chagas disease have access to treatment”); Eric 
Sagonowsky, FDA Blesses Nonprofit-Backed Chagas Drug, 
Thwarting Ex-Shkrei Biotech’s Bid for Rival Launch, FIERCE 
PHARMA (Aug. 20, 2017) (“Chemo Group is a Spanish multinational 
pharma that sells generics and branded drugs, and it runs an 
Argentina-based nonprofit foundation, Mundo Sano.”); see Press 
Release, FDA Approves, supra note 4 (stating that “recent estimates 
are that there may be approximately 300,000 persons in the United 
States with Chagas disease”). 
193 DNDi, Mundo Sano, and Chemo, supra note 190 (stating that 
Chemo Group was “commit[ted] to ensuring [benznidazole] is 
available to the public sector in Chagas-endemic areas on an 
affordable basis”). 
194 BAROFSKY & SCHNEIDER, supra note 176 at 11; Hernández, supra 
note 176 (“The pharmaceutical company Chemo Group had been 
trying to register the drug with the FDA before the disease was even 
tied to the voucher.”). 
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195 Hernández, supra note 176; see BAROFSKY & SCHNEIDER, supra 
note 176 at 11(“DNDi provided technical expertise, including data 
from two DNDi-led clinical trials of benznidazole that were used in 
the FDA application.”). 
196 DNDi, Mundo Sano, and Chemo, supra note 190. 
197 Id. (stating that the funds would “be dedicated to actions that 
benefit patients and encourage access, by supporting not-for-profit 
programs to scale up diagnosis and treatment for Chagas disease”); 
Sagonowsky, supra note 192 (stating that fifty percent of the 
revenue from a PRV sale would fund a ‘far-reaching’ access 
program to ensure supply in the U.S. and other countries); see also 
BAROFSKY & SCHNEIDER, supra note 176 at 11 (noting that in 
addition to providing research data for benznidazole, DNDi is 
searching for new pharmaceutical treatments for Chagas disease); 
U.S. FDA Approves Chemo Group’s Benznidazole to Treat Children 
with Chagas Disease, DNDi (Aug. 31, 2017), 
https://www.dndi.org/2Press Release, FDA, FDA Approves First 
Treatment for Chagas Disease017/media-centre/press-releases/fda-
approves-benznidazole-chagas-children/ (“DNDi is also involved in 
early-stage research for entirely new drugs for Chagas Disease.”). 
198 DNDi, Mundo Sano, and Chemo, supra note 190 (explaining that 
an “affordable basis” would involve “a price that covers 
manufacturing and distribution costs plus a reasonable margin”); cf. 
Hernández, supra note 176 (stating that in its agreement with DNDi 
Chemo Group would “provide benznidazole on a “no profit no loss” 
basis”). 
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  Despite its early setback with Shkreli, KaloBios continued 
its pursuit of FDA approval of benznidazole throughout 2016 and 
into the first half of 2017.199 In December 2016, KaloBios completed 
a face-to-face meeting with the FDA and in January 2017, the FDA 
gave KaloBios positive guidance on benznidazole.200 In May 2017, 
the FDA accepted KaloBios’s Investigational New Drug application 
for benznidazole.201 In July 2017, the FDA granted KaloBios’s 
sponsorship request to designate benznidazole as an orphan drug.202 
                                                 
199 See BRIEF, supra note 186 (stating on December 5, 2016, that 
KaloBios “expect[ed] to have an FDA meeting to confirm regulatory 
pathway for benznidazole in treatment of Chagas disease”); Mole, 
supra note 186 (stating in February 2016 that KaloBios “may now 
be poised for a comeback” and that KaloBios had “renewed [its] 
plan to buy the worldwide regulatory rights to benznidazole from 
Savant”). 
200 JGR CAPITAL PARTNERS, KALOBIOS PHARMACEUTICALS, INC., 1 
(2017), https://www.jgrcap.com/wp-content/uploads/2017/05/KBIO-
May-2-2017-RE.pdf (stating that the “FDA accepted [KaloBios’s] 
intention to use existing safety and efficacy data from previous 
studies”); Press Release, KaloBios Pharmaceuticals, Inc., KaloBios 
Announces Positive Guidance from FDA for Benznidazole (Jan.5, 
2017), https://ir.humanigen.com/press-releases/detail/88/kalobios-
announces-positive-guidance-from-fda-for (“This guidance makes it 
clear that we are on the right track with our development of 
benznidazole, and we expect we will progress expeditiously toward a 
submission . . . .”); KaloBios Pharma (KBIO) Completes Face-to-





Ciara Linnane, KaloBios Stock Jumps on News of Positive Guidance 
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201 Press Release, KaloBios Pharmacueticals, Inc., Benznidazole 
IND for Chagas Disease Receives Clearance by FDA (June 27, 
2017), https://ir.humanigen.com/press-releases/detail/107 .  
202 KaloBios Recieves Orphan Drug Designation for Benznidazole in 




Disease.html; Search Orphan Drug Designations and Approvals 
(Benznidazole),  U.S. FOOD & DRUG ADMIN. (last visited Dec. 25, 
2017), 
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cf
m (hereinafter Search Orphan Drug] (listing a “designated” but not 
approved status for KaloBios’s sponsorship of benznidazole). 
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 However, the FDA had granted Chemo Group orphan drug 
status for benzinidazole back in 2014.203 Although Kalo Bios 
“outlined an approach to pricing benznidaole fairly,”204 Chemo 
Group persisted in its efforts to gain FDA approval.205 Chemo Group 
submitted an NDA with the FDA on December 29, 2016.206  
                                                 
203 Search Orphan Drug, supra note 202 (listing an April 14, 2014 
“designated/approved” date for Chemo Group’s sponsorship of 
benznidazole); see Jeff Antos, Common Misconceptions About the 
Orphan Drug Designation, PHARM. COM. (Mar. 3, 2014), 
http://pharmaceuticalcommerce.com/opinion/common-
misconceptions-about-the-orphan-drug-designation/ (explaining that 
“more than one sponsor can receive an orphan designation for the 
same drug/indication”). 
204 U.S. SEC & EXCH. COMMI’N, FORM 10-K, KALOBIOS 
PHARMACEUTICALS 4 (2017), https://ir.humanigen.com/all-sec-
filings/content/0001214659-17-001799/0001214659-17-001799.pdf 
(“Upon regulatory approval of any of our products, we intend to 
apply our Reasonable Pricing Model, which focuses on affordability 
for patients and payers, transparency for all stakeholders, and 
delivery of a reasonable return in recognition of the risks we are 
taking in our development efforts.”). 
205 See Alpern, supra note 136 (noting that Chemo Group’s efforts 
afforded patients and the medical community “reasons for cautious 
optimism for affordable and dependable access to benznidazole” and 
that “[w]e are left watching and waiting to see who obtains FDA 
approval” for benznidazole). 
206 SUMMARY REVIEW, supra note 143 at 9. 
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B. The FDA Approval of Benznidazole for Chagas Disease 
Finally, on August 29, 2017, the FDA approved Chemo 
Group’s NDA for benznidazole for the treatment of Chagas disease 
in children ages 2 to 12.207 Additionally, the FDA granted Chemo 
Group a PRV.208 
                                                 
207 SUMMARY REVIEW, supra note 143 at 1; Press Release, FDA 
Approves, supra note 4 (“The U.S. Food and Drug Administration 
today granted accelerated approval to benznidazole for use in 
children ages 2 to 12 years with Chagas disease.”); see Hernández, 
supra note 176 (noting that “doctors will still be able to prescribe 
[benznidazole] off-label for adults”); Sagonowsky, supra note 192 
(adding that Chemo Group, Mundo Sano, and  DNDi “picked up 
seven years of orphan drug exclusivity for benznidazole; see also 
Jaime Altcheh et al., Population Pharmacokinetic Study of 
Benznidazole in Pediatric Chagas Disease Suggests Efficacy Despite 
Lower Plasma Concentrations Than in Adults, 8 PLOS NEGLECTED 
TROPICAL DISEASES 2 (2014), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031103/pdf/pntd.0
002907.pdf (stating in the author summary that although “the 
elimination of [benznidazole] is significantly faster in children than 
in adults, leading to lower plasma concentrations . . . . unlike adults, 
all children in the study responded well and had few adverse 
reactions to the drug”); Mario J. Olivera et al., Risk Factors for 
Treatment Interruption and Severe Adverse Effects to Benznidazole 
in Adult Patients with Chagas Disease, PLOS ONE 2 (2017), 
http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.
0185033&type=printable (stating that [i]n some adult [Chagas 
disease] populations the incidence of [adverse drug effects] has 
reached up to 100%”). 
208 Press Release, FDA Approves, supra note 4 (stating that “[w]ith 
this approval, benznidazole’s manufacturer, Chemo Research, S.L., 
is awarded a Tropical Disease Priority Review Voucher in 
accordance with a provision included in the Food and Drug 
Administration Amendment Act of 2007”).  
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 Chemo Group’s pharmaceutical division, Exeltis, will 
distribute benznidazole in the United States.209 Although the FDA 
approval was a victory for the Chemo/Mundo Sano/DNDi group, the 
trio still has challenges to face.210 For example, Chemo Group’s 
ability to affordably provide benznidazole to Chagas patients may 
not be a simple task.211 Because the CDC has treated many U.S. 
Chagas patients for free, some concern exists over these patients’ 
ability to afford and access the drug.212 Additional variables may 
arise, such as providing access to benznidazole through local 
pharmacies and “reach[ing] patients who might not even know they 
are infected.”213 However, the FDA approval of benznidazole 
represents a crucial step in Chagas disease treatment worldwide.214 
                                                 
209 Exeltis US Will Distribute Benznidazole for the Treatment of 
Chagas Disease in Patients 2–12 Years Old, EXELTIS (Aug. 31, 
2017), http://www.exeltis.com/exeltis-us-will-distribute-
benznidazole-treatment-chagas-disease-patients-aged-2-12-years-old 
(“Exeltis will use its operational and technical platform to support 
the availability of benznidazole in the United States in support of 
Mundo Sano—to help minimize cost and ensure compliance with 
FDA regulations”). 
210 Press Release DNDi, supra note 187 (stating that “Chemo Group 
will continue working . . . to overcome barriers to treatment of 
Chagas disease” and that “Mundo Sano and DNDi will pursue 
efforts to boost access and increase patient awareness”).  
211 Columbus, supra note 176 (stating that a concern exists that 
“many Chagas patients will need financial help” and that for some 
patients “almost any price would be too high”). 
212 Id. (noting that “having the CDC supply of the drug has been 
crucial”). 
213 Hernández, supra note 176. 
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214 Press Release DNDi, supra note 187 (“ ‘I am thrilled that we are 
taking a giant step forward in our journey to overcome to many 
barriers to Chagas treatment,’ said Dr. Silvia Gold, President of 
Mundo Sano.”); Drug to Treat Chagas Disease to Become Available 
in the U.S., MÉDECINS SANS FRONTIÈRES (Aug. 31, 2017), 
http://www.doctorswithoutborders.org/article/drug-treat-chagas-
disease-become-available-us [hereinafter MSF Drug to Treat] 
(stating that the “registration and availability of this medicine in the 
United States is a positive step for children with Chagas in the U.S.” 
and that “[w]ithout treatment, many Chagas patients are at risk of 
dying from complications, and few patients in the U.S. currently 
diagnosed and treated for this disease”). 
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IV. CONCLUSION 
 The PRV program played a critical role in helping to bring 
benznidazole to Chagas disease patients in the United States.215 
Although benznidazole had been available to treat Chagas disease 
since 1971, 216 the U.S. pharmaceutical industry ignored the drug 
until the FDA provided the PRV incentive for a Chagas disease 
treatment.217 The time from the FDA’s addition of Chagas disease to 
the list of NTDs to the FDA’s approval of benznidazole for Chagas 
disease was two years and nine days.218 The PRV incentive brought 
two pharmaceutical companies into fierce competition with one 
another to obtain FDA approval for a drug that had existed for more 
than forty years.219 Thus, in the FDA approval of benznidazole, the 
PRV program appears to have succeeded in its original goal to 
“encourage the development of new drug and biological products for 
the prevention and treatment of certain tropical diseases affecting 
millions of people throughout the world.”220 
                                                 
215 Supra text accompanying note 176; see Press Release, FDA 
Approves, supra note 4 (“The FDA granted benznidazole priority 
review . . . because Chagas disease is a rare disease and until now, 
there were no approved drugs for Chagas disease in the United 
States.”). 
216 Supra text accompanying note 143. 
217 MSF Drug to Treat, supra note 214 (“The FDA also announced 
that Chemo will receive a lucrative Priority Review Voucher (PRV) 
for registering benznidazole even though the drug has been used to 
treat Chagas disease in adults in Latin America for more than 40 
years.”). 
218 See 21 C.F.R. § 317 (stating that on August 20, 2017, the FDA 
added Chagas disease to the list of NTDs—the treatment for which 
the FDA would award a PRV upon FDA approval); Press Release, 
FDA Approves, supra note 4 (announcing the FDA approval of 
benznidazole and the FDA’s PRV award to Chemo Group on August 
29, 2017). 
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219 MSF Drug to Treat, supra note 214 (stating that Chemo Group, 
Mundo Sano, and DNDi “beat” KaloBios in the bid for FDA 
approval for benznidazole). 
220 TDPRV GUIDANCE, supra note 68 at 1.  
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 Yet, the original authors of the PRV concept had a more 
expansive goal of “achieving better population health.”221 Ridley et 
al. included two criteria in their paper that Congress did not include 
in the PRV legislation.222 First, the PRV concept’s authors proposed 
that the FDA award PRVs for therapies that are “clinically superior 
to existing treatments.”223 Second, the winner of the PRV should 
“forgo patent rights” for the drug.224 The authors included these 
criteria to further the goal of “help[ing] people suffering from 
neglected diseases who are in need of new medicines that are 
affordable and available regardless of where they live.”225 Including 
these requirements in future legislation would increase the PRV 
program’s ability to truly “develop drugs for developing nations.”226 
 
                                                 
221 See Ridley, Developing Drugs, supra note 20 at 313 (proposing a 
PRV incentive program that “could benefit consumers in both 
developing and developed countries” by “speed[ing] access to highly 
valued treatments”).  
222 Compare Ridley, Developing Drugs, supra note 20 at 315 (“To 
receive a voucher, a therapy must . . . (3) be clinically superior to 
existing treatments, (4) forgo patent rights . . . . ”) with  21 U.S.C. § 
360n (lacking provisions contained in the original proposal paper by 
Ridley et al.). 
223 Ridley, Developing Drugs, supra note 20 at 315. 
224 Id. 
225 David Ridley & Jeffery Moe, An FDA Drug Voucher Program 
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226 Id. (explaining that “limit[ing] vouchers to rewarding only new 
drugs and vaccines . . .will reduce the supply of vouchers and 
increase their price” and that requiring “voucher winners [to] forgo 
their patent rights” would hold drug companies “publically 
accountable to make their treatments available to where it is most 
needed”). 
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 While the benznidazole approval appears to validate the PRV 
program, Chagas patients may have narrowly dodged a bullet.227 
Although legislation enacted in August 2017 that expanded the PRV 
program requirements, additional concerns remain.228 U.S. 
lawmakers should continue refining the PRV program to meet the 
needs of neglected disease patients everywhere.229 
                                                 
227 Hernández, supra note 176 (stating that the “unique agreement” 
between Chemo Group, Mundo Sano, and DNDi “fills in some gaps 
that scholars who created the priority review voucher program 10 
years ago have said they now want to incorporate”); see MSF Drugs 
to Treat, supra note 214 (noting that while it is “good news that 
Chemo has made a commitment to promote access to the drug . . . . 
other companies have abused the PRV program for neglected 
diseases without any benefit to the patient”); see infra note 170 and 
accompanying text. 
228 FDA Reauthorization Act of 2017, Pub. L. No. 115-52, 131 Stat. 
1005, https://www.congress.gov/bill/115th-congress/house-
bill/2430; FDA User Fee Reauthorization Legislation Enacted by 
Congress, ROPES & GRAY (Aug. 7, 2017), 
https://www.ropesgray.com/newsroom/alerts/2017/08/FDA-User-
Fee-Reauthorization-Legislation-Enacted-by-Congress.aspx 
(explaining that the FDA Reauthorization Act tropical disease PRV 
provision requires “applicants to demonstrate they conducted or 
sponsored at least one clinical investigation essential to the 
application”); FDA Reauthorization Act Passes U.S. House and 
Senate Without Fixes to Deliver Urgently Needed New Drugs, 
Vaccines for Neglected Diseases, MÉDECINS SANS FRONTIÈRES 
(Aug. 2, 2107), http://www.doctorswithoutborders.org/article/fda-
reauthorization-act-passes-us-house-and-senate-without-fixes-
deliver-urgently-needed-new (“Both chambers of U.S. Congress 
missed another opportunity to help people living with neglected 
diseases by passing the FDA Reauthorization Act (FDAFA) of 2017 
today without fixing the [FDA’s PRV] program for neglected 
diseases.”); see Ridley & Moe, supra note 225 (“Unfortunately, the 
fix as written to the FDA Reauthorization Act does too little to help 
the millions of people at risk for these diseases.”).  
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229 MSF Drugs to Treat, supra note 214 (“Before a company can 
receive this prize, U.S. Congress should mandate that only new 
medicines receive a PRV and that companies ensure access and 
affordability for all patients.”); Ridley & Moe, supra note 225 
(explaining that Congress should enact “[t]ighter eligibility [that] 
would bolster the value of vouchers by reducing the supply”). 
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